123 results on '"Chu VH"'
Search Results
2. International Society of Cardiovascular Infectious Diseases Guidelines for the Diagnosis, Treatment and Prevention of Disseminated Mycobacterium chimaera Infection Following Cardiac Surgery with Cardiopulmonary Bypass
- Author
-
Hasse, B, Hannan, MM, Keller, PM, Maurer, FP, Sommerstein, R, Mertz, D, Wagner, D, Fernandez-Hidalgo, N, Nomura, J, Manfrin, V, Bettex, D, Conte, AH, Durante-Mangoni, E, Tang, TH-C, Stuart, RL, Lundgren, J, Gordon, S, Jarashow, MC, Schreiber, PW, Niemann, S, Kohl, TA, Daley, CL, Stewardson, AJ, Whitener, CJ, Perkins, K, Plachouras, D, Lamagni, T, Chand, M, Freiberger, T, Zweifel, S, Sander, P, Schulthess, B, Scriven, JE, Sax, H, van Ingen, J, Mestres, CA, Diekema, D, Brown-Elliott, BA, Wallace, RJ, Baddour, LM, Miro, JM, Hoen, B, Athan, E, Bayer, A, Barsic, B, Corey, GR, Chu, VH, Durack, DT, Querido Fortes, C, Fowler, V, Krachmer, AW, Durante-Magnoni, E, Miro, M, Wilson, WR, Striven, J, Stewart, R, Herwaldt, LA, Schreiber, P, Stewardson, A, Widmer, A, Elliot, BAB, Daley, C, Keller, P, Maurer, F, Falk, V, Halbe, M, Perkins, KM, Hasse, B, Hannan, MM, Keller, PM, Maurer, FP, Sommerstein, R, Mertz, D, Wagner, D, Fernandez-Hidalgo, N, Nomura, J, Manfrin, V, Bettex, D, Conte, AH, Durante-Mangoni, E, Tang, TH-C, Stuart, RL, Lundgren, J, Gordon, S, Jarashow, MC, Schreiber, PW, Niemann, S, Kohl, TA, Daley, CL, Stewardson, AJ, Whitener, CJ, Perkins, K, Plachouras, D, Lamagni, T, Chand, M, Freiberger, T, Zweifel, S, Sander, P, Schulthess, B, Scriven, JE, Sax, H, van Ingen, J, Mestres, CA, Diekema, D, Brown-Elliott, BA, Wallace, RJ, Baddour, LM, Miro, JM, Hoen, B, Athan, E, Bayer, A, Barsic, B, Corey, GR, Chu, VH, Durack, DT, Querido Fortes, C, Fowler, V, Krachmer, AW, Durante-Magnoni, E, Miro, M, Wilson, WR, Striven, J, Stewart, R, Herwaldt, LA, Schreiber, P, Stewardson, A, Widmer, A, Elliot, BAB, Daley, C, Keller, P, Maurer, F, Falk, V, Halbe, M, and Perkins, KM
- Abstract
Mycobacterial infection-related morbidity and mortality in patients following cardiopulmonary bypass surgery is high and there is a growing need for a consensus-based expert opinion to provide international guidance for diagnosing, preventing and treating in these patients. In this document the International Society for Cardiovascular Infectious Diseases (ISCVID) covers aspects of prevention (field of hospital epidemiology), clinical management (infectious disease specialists, cardiac surgeons, ophthalmologists, others), laboratory diagnostics (microbiologists, molecular diagnostics), device management (perfusionists, cardiac surgeons) and public health aspects.
- Published
- 2020
3. Association between surgical indications, operative risk, and clinical outcome in infective endocarditis: a prospective study from the International Collaboration on Endocarditis
- Author
-
Chu VH, Park LP, Athan E, Delahaye F, Freiberger T, Lamas C, Miro JM, Mudrick DW, Strahilevitz J, Tribouilloy C, DURANTE MANGONI, Emanuele, Pericas JM, Fernández Hidalgo N, Nacinovich F, Rizk H, Krajinovic V, Giannitsioti E, Hurley JP, Hannan MM, Wang A., Chu, Vh, Park, Lp, Athan, E, Delahaye, F, Freiberger, T, Lamas, C, Miro, Jm, Mudrick, Dw, Strahilevitz, J, Tribouilloy, C, DURANTE MANGONI, Emanuele, Pericas, Jm, Fernández Hidalgo, N, Nacinovich, F, Rizk, H, Krajinovic, V, Giannitsioti, E, Hurley, Jp, Hannan, Mm, and Wang, A.
- Published
- 2015
4. In-Hospital and 1-Year Mortality in Patients Undergoing Early Surgery for Prosthetic Valve Endocarditis
- Author
-
Lalani T, Chu VH, Park LP, Cecchi E, Corey GR, Fowler VG Jr, Gordon D, Grossi P, Hannan M, Hoen B, Muñoz P, Rizk H, Kanj SS, Selton Suty C, Sexton DJ, Spelman D, Ravasio V, Tripodi MF, Wang A., DURANTE MANGONI, Emanuele, Lalani, T, Chu, Vh, Park, Lp, Cecchi, E, Corey, Gr, DURANTE MANGONI, Emanuele, Fowler VG, Jr, Gordon, D, Grossi, P, Hannan, M, Hoen, B, Muñoz, P, Rizk, H, Kanj, S, Selton Suty, C, Sexton, Dj, Spelman, D, Ravasio, V, Tripodi, Mf, and Wang, A.
- Subjects
surgery ,prosthetic valve endocarditis ,in-hospital and 1-year mortality - Published
- 2013
5. Oral presentation: Clinical characteristics and 1 year outcome of cardiac device infective endocarditis
- Author
-
Athan E, Chu VH, Tattevin P, Selton Suty C, Jones P, Naber C, Miro JM, Ninot S, Fernandez Hidalgo N, Spelman D, Hoen B, Lejko Zupanc T, Cecchi E, Thuny F, Hannan M, Pappas P, Henry M, Fowler V, Crowley AL, Wang A., DURANTE MANGONI, Emanuele, Athan, E, Chu, Vh, Tattevin, P, Selton Suty, C, Jones, P, Naber, C, Miro, Jm, Ninot, S, Fernandez Hidalgo, N, DURANTE MANGONI, Emanuele, Spelman, D, Hoen, B, Lejko Zupanc, T, Cecchi, E, Thuny, F, Hannan, M, Pappas, P, Henry, M, Fowler, V, Crowley, Al, and Wang, A.
- Published
- 2011
6. Validated risk score for predicting 6-month mortality in infective endocarditis
- Author
-
Park, LP, Chu, VH, Peterson, G, Skoutelis, A, Lejko-Zupa, T, Bouza, E, Tattevin, P, Habib, G, Tan, R, Gonzalez, J, Altclas, J, Edathodu, J, Fortes, CQ, Siciliano, RF, Pachirat, O, Kanj, S, Wang, A, Clara, L, LSanchez, M, Casabé, J, Cortes, C, Nacinovich, F, Oses, PF, Ronderos, R, Sucari, A, Thierer, J, Spelman, D, Athan, E, Harris, O, Kennedy, K, Gordon, D, Papanicolas, L, Korman, T, Kotsanas, D, Dever, R, Jones, P, Konecny, P, Lawrence, R, Rees, D, Ryan, S, Feneley, MP, Harkness, J, Post, J, Reinbott, P, Gattringer, R, Wiesbauer, F, Andrade, AR, de Brito, ACP, Guimarães, AC, Tranchesi, RADM, Paiva, MG, Ramos, ADO, Weksler, C, Ferraiuoli, G, Golebiovski, W, Lamas, C, James, AK, Keynan, Y, Morris, AM, Rubinstein, E, Jones, SB, Garcia, P, Cereceda, M, Fica, A, Mella, RM, Fernandez, R, Franco, L, Jaramillo, AN, Barsic, B, Bukovski, S, Krajinovic, V, Pangercic, A, Rudez, I, Vincelj, J, Freiberger, T, Pol, J, Zaloudikova, B, Ashour, Z, Kholy, AE, Mishaal, M, Osama, D, Rizk, H, Aissa, N, Alauzet, C, Alla, F, Campagnac, CC, Doco-Lecompte, T, Selton-Suty, C, Delahaye, F, Delahaye, A, Vandenesch, F, Park, LP, Chu, VH, Peterson, G, Skoutelis, A, Lejko-Zupa, T, Bouza, E, Tattevin, P, Habib, G, Tan, R, Gonzalez, J, Altclas, J, Edathodu, J, Fortes, CQ, Siciliano, RF, Pachirat, O, Kanj, S, Wang, A, Clara, L, LSanchez, M, Casabé, J, Cortes, C, Nacinovich, F, Oses, PF, Ronderos, R, Sucari, A, Thierer, J, Spelman, D, Athan, E, Harris, O, Kennedy, K, Gordon, D, Papanicolas, L, Korman, T, Kotsanas, D, Dever, R, Jones, P, Konecny, P, Lawrence, R, Rees, D, Ryan, S, Feneley, MP, Harkness, J, Post, J, Reinbott, P, Gattringer, R, Wiesbauer, F, Andrade, AR, de Brito, ACP, Guimarães, AC, Tranchesi, RADM, Paiva, MG, Ramos, ADO, Weksler, C, Ferraiuoli, G, Golebiovski, W, Lamas, C, James, AK, Keynan, Y, Morris, AM, Rubinstein, E, Jones, SB, Garcia, P, Cereceda, M, Fica, A, Mella, RM, Fernandez, R, Franco, L, Jaramillo, AN, Barsic, B, Bukovski, S, Krajinovic, V, Pangercic, A, Rudez, I, Vincelj, J, Freiberger, T, Pol, J, Zaloudikova, B, Ashour, Z, Kholy, AE, Mishaal, M, Osama, D, Rizk, H, Aissa, N, Alauzet, C, Alla, F, Campagnac, CC, Doco-Lecompte, T, Selton-Suty, C, Delahaye, F, Delahaye, A, and Vandenesch, F
- Abstract
Background-Host factors and complications have been associated with higher mortality in infective endocarditis (IE). We sought to develop and validate a model of clinical characteristics to predict 6-month mortality in IE. Methods and Results-Using a large multinational prospective registry of definite IE (International Collaboration on Endocarditis [ICE]-Prospective Cohort Study [PCS], 2000-2006, n=4049), a model to predict 6-month survival was developed by Cox proportional hazards modeling with inverse probability weighting for surgery treatment and was internally validated by the bootstrapping method. This model was externally validated in an independent prospective registry (ICE-PLUS, 2008-2012, n=1197). The 6-month mortality was 971 of 4049 (24.0%) in the ICE-PCS cohort and 342 of 1197 (28.6%) in the ICE-PLUS cohort. Surgery during the index hospitalization was performed in 48.1% and 54.0% of the cohorts, respectively. In the derivation model, variables related to host factors (age, dialysis), IE characteristics (prosthetic or nosocomial IE, causative organism, left-sided valve vegetation), and IE complications (severe heart failure, stroke, paravalvular complication, and persistent bacteremia) were independently associated with 6-month mortality, and surgery was associated with a lower risk of mortality (Harrell's C statistic 0.715). In the validation model, these variables had similar hazard ratios (Harrell's C statistic 0.682), with a similar, independent benefit of surgery (hazard ratio 0.74, 95% CI 0.62-0.89). A simplified risk model was developed by weight adjustment of these variables. Conclusions-Six-month mortality after IE is 25% and is predicted by host factors, IE characteristics, and IE complications. Surgery during the index hospitalization is associated with lower mortality but is performed less frequently in the highest risk patients. A simplified risk model may be used to identify specific risk subgroups in IE.
- Published
- 2016
7. One-year outcome following biological or mechanical valve replacement for infective endocarditis
- Author
-
Delahaye F, Chu VH, Altclas J, Baršić B, Delahaye A, Freiberger T, Gordon DL, Hannan MM, Hoen B, Kanj SS, Lejko-Zupanc T, Mestres CA, Pachirat O, Pappas P, Lamas C, Selton-Suty C, Tan R, Tattevin P, Wang A and International Collaboration on Endocarditis Prospective Cohort Study (ICE-PCS) Investigators.
- Subjects
prostehtic valves ,infective endocarditis ,valve replacement - Abstract
BACKGROUND: Nearly half of patients require cardiac surgery during the acute phase of infective endocarditis (IE). We describe the characteristics of patients according to the type of valve replacement (mechanical or biological), and examine whether the type of prosthesis was associated with in-hospital and 1-year mortality. METHODS AND RESULTS: Among 5591 patients included in the International Collaboration on Endocarditis Prospective Cohort Study, 1467 patients with definite IE were operated on during the active phase and had a biological (37%) or mechanical (63%) valve replacement. Patients who received bioprostheses were older (62 vs 54years), more often had a history of cancer (9% vs 6%), and had moderate or severe renal disease (9% vs 4%) ; proportion of health care-associated IE was higher (26% vs 17%) ; intracardiac abscesses were more frequent (30% vs 23%). In-hospital and 1-year death rates were higher in the bioprosthesis group, 20.5% vs 14.0% (p=0.0009) and 25.3% vs 16.6% (p
- Published
- 2014
8. One-year outcome following biological or mechanical valve replacement for infective endocarditis
- Author
-
Delahaye, F, Chu, VH, Altclas, J, Barsic, B, Delahaye, A, Freiberger, T, Gordon, DL, Hannan, MM, Hoen, B, Kanj, SS, Lejko-Zupanc, T, Mestres, CA, Pachirat, O, Pappas, P, Lamas, C, Selton-Suty, C, Tan, R, Tattevin, P, Wang, A, Delahaye, F, Chu, VH, Altclas, J, Barsic, B, Delahaye, A, Freiberger, T, Gordon, DL, Hannan, MM, Hoen, B, Kanj, SS, Lejko-Zupanc, T, Mestres, CA, Pachirat, O, Pappas, P, Lamas, C, Selton-Suty, C, Tan, R, Tattevin, P, and Wang, A
- Abstract
BACKGROUND: Nearly half of patients require cardiac surgery during the acute phase of infective endocarditis (IE). We describe the characteristics of patients according to the type of valve replacement (mechanical or biological), and examine whether the type of prosthesis was associated with in-hospital and 1-year mortality. METHODS AND RESULTS: Among 5591 patients included in the International Collaboration on Endocarditis Prospective Cohort Study, 1467 patients with definite IE were operated on during the active phase and had a biological (37%) or mechanical (63%) valve replacement. Patients who received bioprostheses were older (62 vs 54years), more often had a history of cancer (9% vs 6%), and had moderate or severe renal disease (9% vs 4%); proportion of health care-associated IE was higher (26% vs 17%); intracardiac abscesses were more frequent (30% vs 23%). In-hospital and 1-year death rates were higher in the bioprosthesis group, 20.5% vs 14.0% (p=0.0009) and 25.3% vs 16.6% (p<.0001), respectively. In multivariable analysis, mechanical prostheses were less commonly implanted in older patients (odds ratio: 0.64 for every 10years), and in patients with a history of cancer (0.72), but were more commonly implanted in mitral position (1.60). Bioprosthesis was independently associated with 1-year mortality (hazard ratio: 1.298). CONCLUSIONS: Patients with IE who receive a biological valve replacement have significant differences in clinical characteristics compared to patients who receive a mechanical prosthesis. Biological valve replacement is independently associated with a higher in-hospital and 1-year mortality, a result which is possibly related to patient characteristics rather than valve dysfunction.
- Published
- 2015
9. Association between surgical indications, operative risk, and clinical outcome in infective endocarditis: a prospective study from the International Collaboration on Endocarditis.
- Author
-
Chu,VH, Park,LP, Athan,E, Delahaye,F, Freiberger,T, Lamas,C, Miro,JM, Mudrick,DW, Strahilevitz,J, Tribouilloy,C, Durante-Mangoni,E, Pericas,JM, Fernández-Hidalgo,N, Nacinovich,F, Rizk,H, Krajinovic,V, Giannitsioti,E, Hurley,JP, Hannan,MM, Wang,A, Chu,VH, Park,LP, Athan,E, Delahaye,F, Freiberger,T, Lamas,C, Miro,JM, Mudrick,DW, Strahilevitz,J, Tribouilloy,C, Durante-Mangoni,E, Pericas,JM, Fernández-Hidalgo,N, Nacinovich,F, Rizk,H, Krajinovic,V, Giannitsioti,E, Hurley,JP, Hannan,MM, and Wang,A
- Abstract
Use of surgery for the treatment of infective endocarditis (IE) as related to surgical indications and operative risk for mortality has not been well defined.
- Published
- 2014
10. HACEK Infective Endocarditis: Characteristics and Outcomes from a Large, Multi-National Cohort
- Author
-
Chambers, ST, Murdoch, DR, Morris, A, Holland, D, Pappas, P, Almela, M, Ferna´ndez-Hidalgo, N, Almirante, B, Bouza, E, Forno, D, del Rio, A, Hannan, MM, Harkness, J, Kanafani, ZA, Lalani, T, Lang, S, Raymond, N, Read, K, Vinogradova, T, Woods, CW, Wray, D, Corey, GR, Chu, VH, Clara, L, Sanchez, M, Nacinovich, F, Oses, PF, Ronderos, R, Sucari, A, Thierer, J, Casabe´, J, Cortes, C, Altclas, J, Silvia Kogan, S, Spelman, D, Athan, E, Harris, O, Kennedy, K, Tan, R, Gordon, D, Papanicolas, L, Eisen, D, Grigg, L, Street, A, Korman, T, Kotsanas, D, Dever, R, Jones, P, Konecny, P, Lawrence, R, Rees, D, Ryan, S, Feneley, MP, Post, J, Reinbott, P, Gattringer, R, Wiesbauer, F, Andrade, AR, de Brito, ACP, Guimara~es, AC, Grinberg, M, Mansur, AJ, Siciliano, RF, Strabelli, TMV, Vieira, MLC, de Medeiros Tranchesi, RA, Paiva, MG, Fortes, CQ, de Oliveira Ramos, A, Ferraiuoli, G, Golebiovski, W, Lamas, C, Santos, M, Weksler, C, Karlowsky, JA, Keynan, Y, Morris, AM, Rubinstein, E, Jones, SB, Garcia, P, Cereceda, M, Fica, A, Mella, RM, Barsic, B, Bukovski, S, Krajinovic, V, Pangercic, A, Rudez, I, Vincelj, J, Freiberger, T, Pol, J, Zaloudikova, B, Ashour, Z, Kholy, AE, Mishaal, M, Rizk, H, Aissa, N, Alauzet, C, Alla, F, Campagnac, C, Chambers, ST, Murdoch, DR, Morris, A, Holland, D, Pappas, P, Almela, M, Ferna´ndez-Hidalgo, N, Almirante, B, Bouza, E, Forno, D, del Rio, A, Hannan, MM, Harkness, J, Kanafani, ZA, Lalani, T, Lang, S, Raymond, N, Read, K, Vinogradova, T, Woods, CW, Wray, D, Corey, GR, Chu, VH, Clara, L, Sanchez, M, Nacinovich, F, Oses, PF, Ronderos, R, Sucari, A, Thierer, J, Casabe´, J, Cortes, C, Altclas, J, Silvia Kogan, S, Spelman, D, Athan, E, Harris, O, Kennedy, K, Tan, R, Gordon, D, Papanicolas, L, Eisen, D, Grigg, L, Street, A, Korman, T, Kotsanas, D, Dever, R, Jones, P, Konecny, P, Lawrence, R, Rees, D, Ryan, S, Feneley, MP, Post, J, Reinbott, P, Gattringer, R, Wiesbauer, F, Andrade, AR, de Brito, ACP, Guimara~es, AC, Grinberg, M, Mansur, AJ, Siciliano, RF, Strabelli, TMV, Vieira, MLC, de Medeiros Tranchesi, RA, Paiva, MG, Fortes, CQ, de Oliveira Ramos, A, Ferraiuoli, G, Golebiovski, W, Lamas, C, Santos, M, Weksler, C, Karlowsky, JA, Keynan, Y, Morris, AM, Rubinstein, E, Jones, SB, Garcia, P, Cereceda, M, Fica, A, Mella, RM, Barsic, B, Bukovski, S, Krajinovic, V, Pangercic, A, Rudez, I, Vincelj, J, Freiberger, T, Pol, J, Zaloudikova, B, Ashour, Z, Kholy, AE, Mishaal, M, Rizk, H, Aissa, N, Alauzet, C, Alla, F, and Campagnac, C
- Abstract
The HACEK organisms (Haemophilus species, Aggregatibacter species, Cardiobacterium hominis, Eikenella corrodens, and Kingella species) are rare causes of infective endocarditis (IE). The objective of this study is to describe the clinical characteristics and outcomes of patients with HACEK endocarditis (HE) in a large multi-national cohort. Patients hospitalized with definite or possible infective endocarditis by the International Collaboration on Endocarditis Prospective Cohort Study in 64 hospitals from 28 countries were included and characteristics of HE patients compared with IE due to other pathogens. Of 5591 patients enrolled, 77 (1.4%) had HE. HE was associated with a younger age (47 vs. 61 years; p<0.001), a higher prevalence of immunologic/vascular manifestations (32% vs. 20%; p<0.008) and stroke (25% vs. 17% p = 0.05) but a lower prevalence of congestive heart failure (15% vs. 30%; p = 0.004), death in-hospital (4% vs. 18%; p = 0.001) or after 1 year follow-up (6% vs. 20%; p = 0.01) than IE due to other pathogens (n = 5514). On multivariable analysis, stroke was associated with mitral valve vegetations (OR 3.60; CI 1.34-9.65; p<0.01) and younger age (OR 0.62; CI 0.49-0.90; p<0.01). The overall outcome of HE was excellent with the in-hospital mortality (4%) significantly better than for non-HE (18%; p<0.001). Prosthetic valve endocarditis was more common in HE (35%) than non-HE (24%). The outcome of prosthetic valve and native valve HE was excellent whether treated medically or with surgery. Current treatment is very successful for the management of both native valve prosthetic valve HE but further studies are needed to determine why HE has a predilection for younger people and to cause stroke. The small number of patients and observational design limit inferences on treatment strategies. Self selection of study sites limits epidemiological inferences. © 2013 Chambers et al.
- Published
- 2013
11. HACEK Infective Endocarditis: Characteristics and Outcomes from a Large, Multi-National Cohort
- Author
-
Abbate, A, Chambers, ST, Murdoch, D, Morris, A, Holland, D, Pappas, P, Almela, M, Fernandez-Hidalgo, N, Almirante, B, Bouza, E, Forno, D, del Rio, A, Hannan, MM, Harkness, J, Kanafani, ZA, Lalani, T, Lang, S, Raymond, N, Read, K, Vinogradova, T, Woods, CW, Wray, D, Corey, GR, Chu, VH, Clara, L, Sanchez, M, Nacinovich, F, Fernandez Oses, P, Ronderos, R, Sucari, A, Thierer, J, Casabe, J, Cortes, C, Altclas, J, Kogan, S, Spelman, D, Athan, E, Harris, O, Kennedy, K, Tan, R, Gordon, D, Papanicolas, L, Eisen, D, Grigg, L, Street, A, Korman, T, Kotsanas, D, Dever, R, Jones, P, Konecny, P, Lawrence, R, Rees, D, Ryan, S, Feneley, MP, Post, J, Reinbott, P, Gattringer, R, Wiesbauer, F, Andrade, AR, Passos de Brito, AC, Guimaraes, AC, Grinberg, M, Mansur, AJ, Siciliano, RF, Varejao Strabelli, TM, Campos Vieira, ML, de Medeiros Tranchesi, RA, Paiva, MG, Fortes, CQ, Ramos, ADO, Ferraiuoli, G, Golebiovski, W, Lamas, C, Santos, M, Weksler, C, Karlowsky, JA, Keynan, Y, Morris, AM, Rubinstein, E, Jones, SB, Garcia, P, Cereceda, M, Fica, A, Mella, RM, Barsic, B, Bukovski, S, Krajinovic, V, Pangercic, A, Rudez, I, Vincelj, J, Freiberger, T, Pol, J, Zaloudikova, B, Ashour, Z, El Kholy, A, Mishaal, M, Rizk, H, Aissa, N, Alauzet, C, Alla, F, Campagnac, C, Doco-Lecompte, T, Selton-Suty, C, Casalta, J-P, Fournier, P-E, Habib, G, Raoult, D, Thuny, F, Delahaye, F, Delahaye, A, Vandenesch, F, Donal, E, Donnio, PY, Michelet, C, Revest, M, Tattevin, P, Violette, J, Chevalier, F, Jeu, A, Dan, Rusinaru, Sorel, C, Tribouilloy, C, Bernard, Y, Chirouze, C, Hoen, B, Leroy, J, Plesiat, P, Naber, C, Neuerburg, C, Mazaheri, B, Athanasia, S, Giannitsioti, E, Mylona, E, Paniara, O, Papanicolaou, K, Pyros, J, Skoutelis, A, Sharma, G, Francis, J, Nair, L, Thomas, V, Venugopal, K, Hannan, M, Hurley, J, Gilon, D, Israel, S, Korem, M, Strahilevitz, J, Tripodi, MF, Casillo, R, Cuccurullo, S, Dialetto, G, Durante-Mangoni, E, Irene, M, Ragone, E, Utili, R, Cecchi, E, De Rosa, F, Imazio, M, Trinchero, R, Tebini, A, Grossi, P, Lattanzio, M, Toniolo, A, Goglio, A, Raglio, A, Ravasio, V, Rizzi, M, Suter, F, Carosi, G, Magri, S, Signorini, L, Baban, T, Kanafani, Z, Kanj, SS, Sfeir, J, Yasmine, M, Abidin, I, Tamin, SS, Martinez, ER, Nieto, GIS, van der Meer, JTM, Chambers, S, Murdoch, DR, Dragulescu, S, Ionac, A, Mornos, C, Butkevich, OM, Chipigina, N, Kirill, O, Vadim, K, Edathodu, J, Halim, M, Lum, L-N, Tan, R-S, Lejko-Zupanc, T, Logar, M, Mueller-Premru, M, Commerford, P, Commerford, A, Deetlefs, E, Hansa, C, Ntsekhe, M, Armero, Y, Azqueta, M, Castaneda, X, Cervera, C, Falces, C, Garcia-de-la-Maria, C, Fita, G, Gatell, JM, Marco, F, Mestres, CA, Miro, JM, Moreno, A, Ninot, S, Pare, C, Pericas, J, Ramirez, J, Rovira, I, Sitges, M, Anguera, I, Font, B, Guma, JR, Bermejo, J, Garcia Fernandez, MA, Gonzalez-Ramallo, V, Marin, M, Munoz, P, Pedromingo, M, Roda, J, Rodriguez-Creixems, M, Solis, J, Tornos, P, de Alarcon, A, Parra, R, Alestig, E, Johansson, M, Olaison, L, Snygg-Martin, U, Pachirat, O, Pachirat, P, Pussadhamma, B, Senthong, V, Casey, A, Elliott, T, Lambert, P, Watkin, R, Eyton, C, Klein, JL, Bradley, S, Kauffman, C, Bedimo, R, Crowley, AL, Douglas, P, Drew, L, Fowler, VG, Holland, T, Mudrick, D, Samad, Z, Sexton, D, Stryjewski, M, Wang, A, Lerakis, S, Cantey, R, Steed, L, Dickerman, SA, Bonilla, H, DiPersio, J, Salstrom, S-J, Baddley, J, Patel, M, Peterson, G, Stancoven, A, Afonso, L, Kulman, T, Levine, D, Rybak, M, Cabell, CH, Baloch, K, Dixon, CC, Harding, T, Jones-Richmond, M, Park, LP, Redick, T, Stafford, J, Anstrom, K, Bayer, AS, Karchmer, AW, Sexton, DJ, Chu, V, Durack, DT, Phil, D, Eykyn, S, Moreillon, P, Abbate, A, Chambers, ST, Murdoch, D, Morris, A, Holland, D, Pappas, P, Almela, M, Fernandez-Hidalgo, N, Almirante, B, Bouza, E, Forno, D, del Rio, A, Hannan, MM, Harkness, J, Kanafani, ZA, Lalani, T, Lang, S, Raymond, N, Read, K, Vinogradova, T, Woods, CW, Wray, D, Corey, GR, Chu, VH, Clara, L, Sanchez, M, Nacinovich, F, Fernandez Oses, P, Ronderos, R, Sucari, A, Thierer, J, Casabe, J, Cortes, C, Altclas, J, Kogan, S, Spelman, D, Athan, E, Harris, O, Kennedy, K, Tan, R, Gordon, D, Papanicolas, L, Eisen, D, Grigg, L, Street, A, Korman, T, Kotsanas, D, Dever, R, Jones, P, Konecny, P, Lawrence, R, Rees, D, Ryan, S, Feneley, MP, Post, J, Reinbott, P, Gattringer, R, Wiesbauer, F, Andrade, AR, Passos de Brito, AC, Guimaraes, AC, Grinberg, M, Mansur, AJ, Siciliano, RF, Varejao Strabelli, TM, Campos Vieira, ML, de Medeiros Tranchesi, RA, Paiva, MG, Fortes, CQ, Ramos, ADO, Ferraiuoli, G, Golebiovski, W, Lamas, C, Santos, M, Weksler, C, Karlowsky, JA, Keynan, Y, Morris, AM, Rubinstein, E, Jones, SB, Garcia, P, Cereceda, M, Fica, A, Mella, RM, Barsic, B, Bukovski, S, Krajinovic, V, Pangercic, A, Rudez, I, Vincelj, J, Freiberger, T, Pol, J, Zaloudikova, B, Ashour, Z, El Kholy, A, Mishaal, M, Rizk, H, Aissa, N, Alauzet, C, Alla, F, Campagnac, C, Doco-Lecompte, T, Selton-Suty, C, Casalta, J-P, Fournier, P-E, Habib, G, Raoult, D, Thuny, F, Delahaye, F, Delahaye, A, Vandenesch, F, Donal, E, Donnio, PY, Michelet, C, Revest, M, Tattevin, P, Violette, J, Chevalier, F, Jeu, A, Dan, Rusinaru, Sorel, C, Tribouilloy, C, Bernard, Y, Chirouze, C, Hoen, B, Leroy, J, Plesiat, P, Naber, C, Neuerburg, C, Mazaheri, B, Athanasia, S, Giannitsioti, E, Mylona, E, Paniara, O, Papanicolaou, K, Pyros, J, Skoutelis, A, Sharma, G, Francis, J, Nair, L, Thomas, V, Venugopal, K, Hannan, M, Hurley, J, Gilon, D, Israel, S, Korem, M, Strahilevitz, J, Tripodi, MF, Casillo, R, Cuccurullo, S, Dialetto, G, Durante-Mangoni, E, Irene, M, Ragone, E, Utili, R, Cecchi, E, De Rosa, F, Imazio, M, Trinchero, R, Tebini, A, Grossi, P, Lattanzio, M, Toniolo, A, Goglio, A, Raglio, A, Ravasio, V, Rizzi, M, Suter, F, Carosi, G, Magri, S, Signorini, L, Baban, T, Kanafani, Z, Kanj, SS, Sfeir, J, Yasmine, M, Abidin, I, Tamin, SS, Martinez, ER, Nieto, GIS, van der Meer, JTM, Chambers, S, Murdoch, DR, Dragulescu, S, Ionac, A, Mornos, C, Butkevich, OM, Chipigina, N, Kirill, O, Vadim, K, Edathodu, J, Halim, M, Lum, L-N, Tan, R-S, Lejko-Zupanc, T, Logar, M, Mueller-Premru, M, Commerford, P, Commerford, A, Deetlefs, E, Hansa, C, Ntsekhe, M, Armero, Y, Azqueta, M, Castaneda, X, Cervera, C, Falces, C, Garcia-de-la-Maria, C, Fita, G, Gatell, JM, Marco, F, Mestres, CA, Miro, JM, Moreno, A, Ninot, S, Pare, C, Pericas, J, Ramirez, J, Rovira, I, Sitges, M, Anguera, I, Font, B, Guma, JR, Bermejo, J, Garcia Fernandez, MA, Gonzalez-Ramallo, V, Marin, M, Munoz, P, Pedromingo, M, Roda, J, Rodriguez-Creixems, M, Solis, J, Tornos, P, de Alarcon, A, Parra, R, Alestig, E, Johansson, M, Olaison, L, Snygg-Martin, U, Pachirat, O, Pachirat, P, Pussadhamma, B, Senthong, V, Casey, A, Elliott, T, Lambert, P, Watkin, R, Eyton, C, Klein, JL, Bradley, S, Kauffman, C, Bedimo, R, Crowley, AL, Douglas, P, Drew, L, Fowler, VG, Holland, T, Mudrick, D, Samad, Z, Sexton, D, Stryjewski, M, Wang, A, Lerakis, S, Cantey, R, Steed, L, Dickerman, SA, Bonilla, H, DiPersio, J, Salstrom, S-J, Baddley, J, Patel, M, Peterson, G, Stancoven, A, Afonso, L, Kulman, T, Levine, D, Rybak, M, Cabell, CH, Baloch, K, Dixon, CC, Harding, T, Jones-Richmond, M, Park, LP, Redick, T, Stafford, J, Anstrom, K, Bayer, AS, Karchmer, AW, Sexton, DJ, Chu, V, Durack, DT, Phil, D, Eykyn, S, and Moreillon, P
- Abstract
The HACEK organisms (Haemophilus species, Aggregatibacter species, Cardiobacterium hominis, Eikenella corrodens, and Kingella species) are rare causes of infective endocarditis (IE). The objective of this study is to describe the clinical characteristics and outcomes of patients with HACEK endocarditis (HE) in a large multi-national cohort. Patients hospitalized with definite or possible infective endocarditis by the International Collaboration on Endocarditis Prospective Cohort Study in 64 hospitals from 28 countries were included and characteristics of HE patients compared with IE due to other pathogens. Of 5591 patients enrolled, 77 (1.4%) had HE. HE was associated with a younger age (47 vs. 61 years; p<0.001), a higher prevalence of immunologic/vascular manifestations (32% vs. 20%; p<0.008) and stroke (25% vs. 17% p = 0.05) but a lower prevalence of congestive heart failure (15% vs. 30%; p = 0.004), death in-hospital (4% vs. 18%; p = 0.001) or after 1 year follow-up (6% vs. 20%; p = 0.01) than IE due to other pathogens (n = 5514). On multivariable analysis, stroke was associated with mitral valve vegetations (OR 3.60; CI 1.34-9.65; p<0.01) and younger age (OR 0.62; CI 0.49-0.90; p<0.01). The overall outcome of HE was excellent with the in-hospital mortality (4%) significantly better than for non-HE (18%; p<0.001). Prosthetic valve endocarditis was more common in HE (35%) than non-HE (24%). The outcome of prosthetic valve and native valve HE was excellent whether treated medically or with surgery. Current treatment is very successful for the management of both native valve prosthetic valve HE but further studies are needed to determine why HE has a predilection for younger people and to cause stroke. The small number of patients and observational design limit inferences on treatment strategies. Self selection of study sites limits epidemiological inferences.
- Published
- 2013
12. Clinical characteristics and outcome of infective endocarditis involving implantable cardiac devices.
- Author
-
Athan E, Chu VH, Tattevin P, Selton-Suty C, Jones P, Naber C, Miró JM, Ninot S, Fernández-Hidalgo N, Durante-Mangoni E, Spelman D, Hoen B, Lejko-Zupanc T, Cecchi E, Thuny F, Hannan MM, Pappas P, Henry M, Fowler VG Jr, and Crowley AL
- Abstract
Context: Infection of implantable cardiac devices is an emerging disease with significant morbidity, mortality, and health care costs.Objectives: To describe the clinical characteristics and outcome of cardiac device infective endocarditis (CDIE) with attention to its health care association and to evaluate the association between device removal during index hospitalization and outcome.Design, Setting, and Patients: Prospective cohort study using data from the International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS), conducted June 2000 through August 2006 in 61 centers in 28 countries. Patients were hospitalized adults with definite endocarditis as defined by modified Duke endocarditis criteria.Main Outcome Measures: In-hospital and 1-year mortality.Results: CDIE was diagnosed in 177 (6.4% [95% CI, 5.5%-7.4%]) of a total cohort of 2760 patients with definite infective endocarditis. The clinical profile of CDIE included advanced patient age (median, 71.2 years [interquartile range, 59.8-77.6]); causation by staphylococci (62 [35.0% {95% CI, 28.0%-42.5%}] Staphylococcus aureus and 56 [31.6% {95% CI, 24.9%-39.0%}] coagulase-negative staphylococci); and a high prevalence of health care-associated infection (81 [45.8% {95% CI, 38.3%-53.4%}]). There was coexisting valve involvement in 66 (37.3% [95% CI, 30.2%-44.9%]) patients, predominantly tricuspid valve infection (43/177 [24.3%]), with associated higher mortality. In-hospital and 1-year mortality rates were 14.7% (26/177 [95% CI, 9.8%-20.8%]) and 23.2% (41/177 [95% CI, 17.2%-30.1%]), respectively. Proportional hazards regression analysis showed a survival benefit at 1 year for device removal during the initial hospitalization (28/141 patients [19.9%] who underwent device removal during the index hospitalization had died at 1 year, vs 13/34 [38.2%] who did not undergo device removal; hazard ratio, 0.42 [95% CI, 0.22-0.82]).Conclusions: Among patients with CDIE, the rate of concomitant valve infection is high, as is mortality, particularly if there is valve involvement. Early device removal is associated with improved survival at 1 year. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
13. Analysis of the impact of early surgery on in-hospital mortality of native valve endocarditis: use of propensity score and instrumental variable methods to adjust for treatment-selection bias.
- Author
-
Lalani T, Cabell CH, Benjamin DK, Lasca O, Naber C, Fowler VG Jr, Corey GR, Chu VH, Fenely M, Pachirat O, Tan RS, Watkin R, Ionac A, Moreno A, Mestres CA, Casabé J, Chipigina N, Eisen DP, Spelman D, and Delahaye F
- Published
- 2010
- Full Text
- View/download PDF
14. Coagulase-negative staphylococcal prosthetic valve endocarditis--a contemporary update based on the International Collaboration on Endocarditis: prospective cohort study.
- Author
-
Chu VH, Miro JM, Hoen B, Cabell CH, Pappas PA, Jones P, Stryjewski ME, Anguera I, Braun S, Muñoz P, Commerford P, Tornos P, Francis J, Oyonarte M, Selton-Suty C, Morris AJ, Habib G, Almirante B, Sexton DJ, and Corey GR
- Abstract
OBJECTIVE: To describe the contemporary features of coagulase-negative staphylococcal (CoNS) prosthetic valve endocarditis (PVE). DESIGN: Observational study of prospectively collected data from a multinational cohort of patients with infective endocarditis. Patients with CoNS PVE were compared to patients with Staphylococcus aureus and viridans streptococcal (VGS) PVE. SETTING: The International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS) is a contemporary cohort of patients with infective endocarditis from 61 centres in 28 countries. PATIENTS: Adult patients in the ICE-PCS with definite PVE and no history of injecting drug use from June 2000 to August 2005 were included. INTERVENTIONS: None. MAIN OUTCOME MEASURES: Heart failure, intracardiac abscess, death. RESULTS: CoNS caused 16% (n = 86) of 537 cases of definite non-injecting drug use-associated PVE. Nearly one-half (n = 33/69, 48%) of patients with CoNS PVE presented between 60 days and 365 days of valve implantation. The rate of intracardiac abscess was significantly higher in patients with CoNS PVE (38%) than in patients with either S aureus (23%, p = 0.03) or VGS (20%, p = 0.05) PVE. The rate of abscess was particularly high in early (50%) and intermediate (52%) CoNS PVE. In-hospital mortality was 24% for CoNS PVE, 36% for S aureus PVE (p = 0.09) and 9.1% for VGS PVE (p = 0.08). Meticillin resistance was present in 68% of CoNS strains. CONCLUSIONS: Nearly one-half of CoNS PVE cases occur between 60 days and 365 days of prosthetic valve implantation. CoNS PVE is associated with a high rate of meticillin resistance and significant valvular complications. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
15. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study.
- Author
-
Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG Jr, Bayer AS, Karchmer AW, Olaison L, Pappas PA, Moreillon P, Chambers ST, Chu VH, Falcó V, Holland DJ, Jones P, Klein JL, Raymond NJ, Read KM, Tripodi MF, and Utili R
- Published
- 2009
- Full Text
- View/download PDF
16. Expression of antimicrobial peptides in the normal and involved skin of patients with infective cellulitis.
- Author
-
Stryjewski ME, Hall RP, Chu VH, Kanafani ZA, O'riordan WD, Weinstock MS, Stienecker RS, Streilein R, Dorschner RA, Fowler VG Jr, Corey GR, Gallo RL, Stryjewski, Martin E, Hall, Russell P, Chu, Vivian H, Kanafani, Zeina A, O'Riordan, William D, Weinstock, Michael S, Stienecker, R Scott, and Streilein, Robert
- Abstract
Background: Endogenous antimicrobial peptides participate in the innate defense of skin against a variety of pathogens. The systemic expression of these peptides in normal-appearing skin of patients with infective cellulitis is unknown.Methods: Study patients were adults with infective cellulitis and signs of systemic inflammation. Skin biopsy and serum specimens were obtained from patients and from control subjects with no active infection. Cathelicidin and human beta-defensin 2 mRNA expression were determined by real-time polymerase chain reaction.Results: Skin biopsy specimens from 11 patients and 4 uninfected control subjects were analyzed. The relative expression level for cathelicidin mRNA was elevated in both the involved and the distal normal-appearing skin of patients with cellulitis, compared with expression in the skin of control subjects (mean ratios, 39.46 vs. 1.32, P=.0059; and 21.41 vs. 1.32, P=.0059). Similarly, the relative expression level of human beta -defensin 2 mRNA was elevated in both the involved skin (mean ratios, 20,844 vs. 11.65; P=.0015) and in distal normal-appearing skin of patients with cellulitis (mean ratios, 201.1 vs. 11.65; P=.0103).Discussion: In response to cutaneous infection there is a local and distal increase in endogenous antimicrobial peptide mRNA in both involved and normal-appearing skin. These observations show, for the first time to our knowledge, that after infection the human body responds by increasing systemic innate immunity. [ABSTRACT FROM AUTHOR]- Published
- 2007
- Full Text
- View/download PDF
17. Early predictors of in-hospital death in infective endocarditis.
- Author
-
Chu VH, Cabell CH, Benjamin DK Jr., Kuniholm EF, Fowler VG Jr., Engemann J, Sexton DJ, Corey GR, Wang A, Chu, Vivian H, Cabell, Christopher H, Benjamin, Daniel K Jr, Kuniholm, Erin F, Fowler, Vance G Jr, Engemann, John, Sexton, Daniel J, Corey, G Ralph, and Wang, Andrew
- Published
- 2004
18. Echocardiographic risk stratification for early surgery with endocarditis: a cost-effectiveness analysis.
- Author
-
Liao L, Kong DF, Samad Z, Pappas PA, Jollis JG, Lin SS, Wang A, Fowler VG Jr, Chu VH, Sexton DJ, Corey GR, Cabell CH, Liao, L, Kong, D F, Samad, Z, Pappas, P A, Jollis, J G, Lin, S S, Wang, A, and Fowler, V G Jr
- Abstract
Background: Despite widespread acceptance of echocardiography for diagnosis of infective endocarditis, few investigators have evaluated its utility as a risk-stratification tool to aid therapeutic decision-making.Methods: A decision tree and Markov analysis model were constructed using published and institutional data to estimate the cost-effectiveness of an echocardiographic risk-stratification strategy for infective endocarditis. The models compared surgery for high-risk patients based on clinical factors ("standard care") and surgery for high-risk patients based on echocardiographic findings ("echocardiography-guided").Results: The cost per patient for standard care and echocardiography-guided strategies was $47,766 and $53,669, respectively. The expected quality-adjusted life years (QALY) for standard care and echocardiography-guided strategies were 5.86 years and 6.10 years, respectively. Compared with standard care, the echocardiography-guided strategy cost an additional $23,867 per QALY saved. In one-way sensitivity analyses, the incremental cost of this strategy remained <$50,000/QALY across a broad range of scenarios. Baseline stroke risk had the greatest effect on cost-effectiveness. For populations with stroke risk less than 3.65%, the echocardiography-guided strategy was not cost-attractive (ICER >$50,000/QALY). At stroke risk between 3.65% and 14%, the ICER for the echocardiography-guided strategy was attractive (<$50,000 /QALY). The echocardiography-guided strategy became economically dominant at any baseline stroke risk greater than 18.3%.Conclusion: Echo-guided risk stratification for early surgery in patients with large vegetations is a cost-attractive treatment strategy for IE, as it improves outcome for an incremental cost <$50,000/QALY. [ABSTRACT FROM AUTHOR]- Published
- 2008
- Full Text
- View/download PDF
19. Influence of Vancomycin Minimum Inhibitory Concentration on the Outcome of Methicillin-Susceptible Staphylococcus aureus Left-Sided Infective Endocarditis Treated with Anti-staphylococcal Beta-Lactam Antibiotics; a Prospective Cohort Study by the International Collaboration on Endocarditis
- Author
-
Athan, E., Harris, O., Korman, T. M., Kotsanas, D., Jones, P., Reinbott, P., Ryan, S., Fortes, C. Q., Garcia, P., Jones, S. B., Barsic, B., Bukovski, S., Selton-Suty, C., Aissa, N., Doco-Lecompte, T., Delahaye, F., Vandenesch, F., Tattevin, P., Hoen, B., Plesiat, P., Giamarellou, H., Giannitsioti, E., Tarpatzi, E., Durante-Mangoni, E., Iossa, D., Orlando, S., Ursi, M. P., Pafundi, P. C., D' Amico, F., Bernardo, M., Cuccurullo, S., Dialetto, G., Covino, F. E., Manduca, S., Della Corte, A., De Feo, M., Tripodi, M. F., Baban, T., Kanafani, Z. A., Kanj, S. S., Sfeir, J., Yasmine, M., Morris, A., Murdoch, D. R., Premru, M. M., Lejko-Zupanc, T., Almela, M., Ambrosioni, J., Azqueta, M., Brunet, M., Cervera, C., De Lazzari, E., Falces, C., Fuster, D., Garcia-de-la-Maria, C., Garcia-Gonzalez, J., Gatell, J. M., Marco, F., Miro, J. M., Moreno, A., Ortiz, J., Ninot, S., Pare, J. C., Pericas, J. M., Quintana, E., Ramirez, J., Sandoval, E., Sitges, M., Tolosana, J. M., Vidal, B., Vila, J., Bouza, E., Rodriguez-Creixems, M., Ramallo, V., Bradley, S., Wray, D., Steed, L., Cantey, R., Peterson, G., Stancoven, A., Woods, C., Corey, G. R., Reller, L. B., Fowler, V. G., Chu, V. H., Messina, J. A., Park, L., Sharma-Kuinkel, B. K., Carugati, M., Munoz, P., Baloch, K., Dixon, C. C., Harding, T., Jones-Richmond, M., Pappas, P., Park, L. P., Redick, T., Stafford, J., Anstrom, K., Bayer, A. S., Cabell, C. H., Karchmer, A. W., Sexton, D. J., Wang, A., Chu, V., Durack, D. T., Eykyn, S., Moreillon, P., Olaison, L., Raoult, D., Rubinstein, E., Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Duke University Medical Center, University of Barcelona, Medical University of South Carolina [Charleston] (MUSC), American University of Beirut [Beyrouth] (AUB), Service des maladies infectieuses et réanimation médicale [Rennes] = Infectious Disease and Intensive Care [Rennes], CHU Pontchaillou [Rennes], Université de Tsukuba = University of Tsukuba, Pericàs, J M, Messina, J A, Garcia-de-la-Mària, C, Park, L, Sharma-Kuinkel, B K, Marco, F, Wray, D, Kanafani, Z A, Carugati, M, Durante Mangoni, E, Tattevin, P, Chu, V H, Moreno, A, Fowler, V G, Miró, J M, De Feo, Marisa, Athan, E11, Harris, O11, Korman, Tm12, Kotsanas, D13, Jones, P14, Reinbott, P14, Ryan, S14, Fortes, Cq15, Garcia, P16, Jones, Sb16, Barsic, B17, Bukovski, S17, Selton-Suty, C18, Aissa, N18, Doco-Lecompte, T18, Delahaye, F19, Vandenesch, F19, Tattevin, P20, Hoen, B21, Plesiat, P21, Giamarellou, H22, Giannitsioti, E22, Tarpatzi, E22, Durante-Mangoni, E23, Iossa, D23, Orlando, S23, Ursi, Mp23, Pafundi, Pc23, D' Amico, F23, Bernardo, M23, Cuccurullo, S23, Dialetto, G23, Covino, Fe23, Manduca, S23, DELLA CORTE, Alessandro, De Feo, M23, Tripodi, Mf24, Baban, T25, Kanafani, Za25, Kanj, Ss25, Sfeir, J25, Yasmine, M25, Morris, A26, Murdoch, Dr27, Premru, Mm28, Lejko-Zupanc, T28, Almela, M29, Ambrosioni, J29, Azqueta, M29, Brunet, M29, Cervera, C29, De Lazzari, E29, Falces, C29, Fuster, D29, Garcia-de-la-Mària, C29, Garcia-Gonzalez, J29, Gatell, Jm29, Marco, F29, Miró, Jm29, Moreno, A29, Ortiz, J29, Ninot, S29, Paré, Jc29, Pericas, Jm29, Quintana, E29, Ramirez, J29, Sandoval, E29, Sitges, M29, Tolosana, Jm29, Vidal, B29, Vila, J29, Bouza, E30, Muñoz, P, Rodríguez-Créixems, M30, Ramallo, V30, Bradley, S31, Wray, D32, Steed, L32, Cantey, R32, Peterson, G33, Stancoven, A33, Woods, C34, Corey, Gr34, Reller, Lb34, Fowler VG, Jr34, Chu, Vh34, Baloch, K, Chu, Vh, Corey, Gr, Dixon, Cc, Fowler VG, Jr, Harding, T, Jones-Richmond, M, Pappas, P, Park, Lp, Redick, T, Stafford, J, Anstrom, K, Athan, E, Bayer, A, Cabell, Ch, Hoen, B, Karchmer, Aw, Miró, Jm, Murdoch, Dr, Sexton, Dj, Wang, A, Chu, V, Durack, Dt, Eykyn, S, Moreillon, P, Olaison, L, Raoult, D, Rubinstein, E, and Sexton, Dj.
- Subjects
0301 basic medicine ,Male ,medicine.disease_cause ,0302 clinical medicine ,80 and over ,Medicaments antibacterians ,030212 general & internal medicine ,Endocarditi ,Prospective Studies ,Aged, 80 and over ,Endocarditis ,Bacterial ,General Medicine ,Middle Aged ,Staphylococcal Infections ,3. Good health ,Anti-Bacterial Agents ,Fenotip ,Infectious Diseases ,[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology ,Treatment Outcome ,Phenotype ,Staphylococcus aureus ,Infective endocarditis ,Staphylococcus aureu ,Vancomycin ,Genotype ,Vancomycin MIC ,Adult ,Aged ,Endocarditis, Bacterial ,Female ,Humans ,Microbial Sensitivity Tests ,Molecular Typing ,Multiplex Polymerase Chain Reaction ,Survival Analysis ,Virulence Factors ,beta-Lactams ,medicine.drug ,Microbiology (medical) ,030106 microbiology ,Biology ,Staphylococcal infections ,Article ,Microbiology ,03 medical and health sciences ,Minimum inhibitory concentration ,medicine ,Etest ,Endocarditis Staphylococcus aureus ,biochemical phenomena, metabolism, and nutrition ,medicine.disease ,Antibacterial agents ,Methicillin Susceptible Staphylococcus Aureus - Abstract
Objectives: Left-sided methicillin-susceptible Staphylococcus aureus (MSSA) endocarditis treated with cloxacillin has a poorer prognosis when the vancomycin minimum inhibitory concentration (MIC) is >= 1.5 mg/L. We aimed to validate this using the International Collaboration on Endocarditis cohort and to analyse whether specific genetic characteristics were associated with a high vancomycin MIC (> 1.5mg/L) phenotype.Methods: All patients with left-sided MSSA infective endocarditis treated with antistaphylococcal beta-lactam antibiotics between 2000 and 2006 with available isolates were included. Vancomycin MIC was determined by Etest as either high (>= 1.5 mg/L) or low (
- Published
- 2017
- Full Text
- View/download PDF
20. Methicillin-Susceptible Staphylococcus aureus Endocarditis Isolates Are Associated With Clonal Complex 30 Genotype and a Distinct Repertoire of Enterotoxins and Adhesins
- Author
-
Tony M. Korman, Thanh Doco-Lecompte, Mercedes Marín, Juhsien J.C. Nienaber, David R. Murdoch, Vance G. Fowler, G. Ralph Corey, L. Barth Reller, Steve Barriere, Lawrence P. Park, Suzana Bukovski, Thomas H. Rude, Christopher W. Woods, Batu K. Sharma Kuinkel, Supaporn Lamlertthon, Michael Clarke-Pearson, Patricia García, Vivian H. Chu, Nienaber, Jj, Sharma Kuinkel, Bk, Clarke Pearson, M, Lamlertthon, S, Park, L, Rude, Th, Barriere, S, Woods, Cw, Chu, Vh, Marín, M, Bukovski, S, Garcia, P, Corey, Gr, Korman, T, Doco Lecompte, T, Murdoch, Dr, Reller, Lb, Fowler VG, Jr, among International Collaboration on Endocarditis Microbiology, Investigator, and Utili, Riccardo
- Subjects
Adult ,DNA, Bacterial ,Male ,Staphylococcus aureus ,Genotype ,Virulence Factors ,Biology ,medicine.disease_cause ,Staphylococcal infections ,Severity of Illness Index ,Microbiology ,Major Articles and Brief Reports ,Enterotoxins ,Middle East ,medicine ,Humans ,Immunology and Allergy ,Endocarditis ,Adhesins, Bacterial ,Aged ,Soft Tissue Infections ,Australia ,Endocarditis, Bacterial ,Middle Aged ,Staphylococcal Infections ,medicine.disease ,Bacterial Typing Techniques ,Europe ,Bacterial adhesin ,Infectious Diseases ,Infective endocarditis ,North America ,Multilocus sequence typing ,Female ,Methicillin Resistance ,endocarditis ,Methicillin Susceptible Staphylococcus Aureus ,Multilocus Sequence Typing ,New Zealand - Abstract
Staphylococcus aureus is the most common cause of both infective endocarditis (IE) [1] and soft tissue infection (STI) [2] in the industrialized world. The frequency of S. aureus as a human pathogen is thought to be due in part to its diverse armamentarium of virulence-associated genes. Although substantial evidence suggests that clinical manifestations of S. aureus are influenced by the genetic characteristics of the infecting strain [3–7], the association between S. aureus genes and severity of illness is incompletely understood. Previously, we demonstrated a significant association between specific S. aureus isolates genotypes and infection severity [4]. We used multilocus sequence typing (MLST) to show that clonal complex (CC) 5 and CC30 were significantly associated with the presence of IE and bone and joint infection among 371 clinically well-characterized S. aureus isolates from a single geographical region. However, these findings must be confirmed prior to being considered broadly generalizable. The current investigation seeks to externally validate these previously observed associations between bacterial genotype and infection severity in S. aureus. To do this, we used bacterial isolates from 2 large multinational cohorts of patients with distinct forms of staphylococcal disease: IE and STI.
- Published
- 2011
- Full Text
- View/download PDF
21. Impact of early valve surgery on outcome of Staphylococcus aureus prosthetic valve infective endocarditis: analysis in the International Collaboration of Endocarditis-Prospective Cohort Study
- Author
-
Richard Watkin, Pierre-Edouard Fournier, David R. Murdoch, Yoav Keynan, Florent Chevalier, Tania Mara Varejão Strabelli, Imran Zainal Abidin, Denis Spelman, Roger Bedimo, Jeffrey J. Post, Francesc Marco, Alan C Street, Claudio Querido Fortes, Francisco Nacinovich, Antonio Goglio, Stephen T. Chambers, Fredy Suter, Claire Sorel, Alessandro Tebini, Phillip Jones, Robyn Dever, Emilio Bouza, G. Ralph Corey, Karina Kennedy, Alfredo José Mansur, Nigel Raymond, Guillermina Fita, Martin E. Stryjewski, Joan R. Guma, Asunción Moreno, John W. Baddley, Johnson Francis, Magnus Johansson, José H. Casabé, Margaret M. Hannan, Krishnan Venugopal, Thanh Doco-Lecompte, Jacob Strahilevitz, Annibale Raglio, Carl Neuerburg, Vichai Senthong, Cass Hansa, Ana Pangerčić, Adina Ionac, Vladimir Krajinović, Christine Selton-Suty, Marwa Mishaal, Mateja Logar, Erwan Donal, Elena Mylona, Clara Weksler, Joseph Di Persio, Antoine Jeu, Pilar Tornos, Konstantinos Papanicolaou, François Vandenesch, Tom S.J. Elliott, Jan van der Meer, Patricia Muñoz, Regina Aparecida De Medeiros Tranchesi, Lathi Nair, Dannah Wray, Arnold S. Bayer, Pamela Konecny, David L. Gordon, Gilbert Habib, Armênio Costa Guimarães, Alberto Fica, Mercedes Marín, Francesco Giuseppe De Rosa, Marian Jones-Richmond, Marcelo Luiz Campos Vieira, Max Grinberg, Luis Afonso, Khaula Baloch, Pimchitra Pachirat, Anna Lisa Crowley, Marie Line Erpelding, Miguel Pedromingo, Daniel W. Mudrick, John Harkness, Barbora Zaloudikova, Christophe Tribouilloy, Cristina Garcia-de-la-Maria, Kerry Read, Athanasios Skoutelis, Marco Rizzi, Michael J. Rybak, Ioannis Deliolanis, Stuart Dickerman, Carol A. Kauffman, John L Klein, Suzanne Ryan, Christopher W. Woods, Gautam Sharma, Silvia Magri, Susannah J. Eykyn, Veronica Ravasio, Auristela De Oliveira Ramos, J. Leroy, Bruno Baršić, Burabha Pussadhamma, Jameela Edathodu, Franck Thuny, Eduan Deetlefs, Yvette Bernard, Rinaldo Focaccia Siciliano, Lito E. Papanicolas, Salvador Ninot, Nuria Fernández-Hidalgo, Zaniab Samad, Arístides de Alarcón, Neijla Aissa, Claudia Cortés, Thomas L. Holland, Tina Harding, Tania A. Baban, Irene Rovira, Ethan Rubinstein, Jorge Solis, Maya Korem, Giampiero Carosi, Marie Francoise Tripodi, Andrew Wang, Orathai Pachirat, Davide Forno, Ana Cláudia Passos De Brito, Catherine Campagnac, Anna L. Casey, Ana del Río, Gail E. Peterson, Carlos Falces, Christopher H. Cabell, François Delahaye, Emanuele Durante-Mangoni, Mattucci Irene, Despina Kotsanas, Javier Bermejo, Pierre Tattevin, Richard Lawrence, John Pyros, José M. Gatell, Jérémie Violette, Igor Rudez, Peter A. Lambert, Jean Paul Casalta, Jiri Pol, Kulichenko Vadim, Pablo Fernandez Oses, Ximena Castañeda, José Ramírez, Rita Trinchero, Sarah Israel, Mariangela Lattanzio, Eugene Athan, Arthur J. Morris, Bahram Mazaheri, Leeanne Grigg, Mohamad Yasmine, Adriana Andrade, Owen Harris, Syahidah Syed Tamin, Adolf W. Karchmer, Joan Pericas, Manica Mueller-Premru, Ozerecky Kirill, Eduardo Rivera Martínez, Christina Eyton, Josip Vincelj, Marisa Santos, Marisa Sanchez, David T. Durack, Dan Gilon, Marcelo Goulart Paiva, G. Ferraiuoli, Susanna Cuccurullo, Chipigina Ns, Lars Olaison, Patrick Plésiat, Michael P. Feneley, Amy B. Stancoven, Efthymia Giannitsioti, Cristiane da Cruz Lamas, Silvia Kogan, Kevin J. Anstrom, Manuel Almela, Liliana Clara, Stamatios Lerakis, Massimo Imazio, Rainer Gattringer, Javier Altclas, Wilma F. Golebiovski, Cristian Mornos, Damon P. Eisen, Pierre-Yves Donnio, Bernat Font, Eric Alestig, Liana Signorini, Sandra Braun Jones, Pamela S. Douglas, Helen Giamarellou, Gabriel Israel Soto Nieto, Tatjana Lejko-Zupanc, Benito Almirante, Dan Rusinaru, Anita Commerford, Yolanda Armero, Donald P. Levine, Mukesh Patel, M. Azqueta, Mpiko Ntsekhe, Phillipe Moreillon, Matthieu Revest, Adriana Sucari, Ashour Zainab, Olga Paniara, Víctor González-Ramallo, Miguel Ángel García Fernández, Ricardo Parra, Christoph Naber, Hector Bonilla, John P. Hurley, Rodrigo Montagna Mella, James A. Karlowsky, Lisa L. Steed, Armelle Delahaye, Marta Rodríguez-Créixems, José M. Miró, Enrico Cecchi, Enrico Ragone, Catherine Chirouze, J. Roda, David Holland, Marta Sitges, Luh Nah Lum, Patricia García, Thomas Redick, Theresa Kulman, Paul A. Pappas, Carlos Paré, Riccardo Utili, Stefan Dragulescu, Robert Cantey, Paolo Grossi, Vivian H. Chu, Porl Reinbott, Bruno Hoen, Amani El Kholy, Judy Stafford, Tomáš Freiberger, Hussien Rizk, Corentine Alauzet, Ricardo Ronderos, Ru San Tan, Christian Michelet, Suzanne F. Bradley, R. Casillo, Thomas Tsaganos, M. Cereceda, Laura A. Drew, Magid Halim, François Alla, Tahaniyat Lalani, Carlos A. Mestres, David Rees, Sara Jane Salstrom, O. M. Butkevich, Patrick J. Commerford, Ignasi Anguera, Franz Wiesbauer, Ulrika Snygg-Martin, Lawrence P. Park, Didier Raoult, Tony M. Korman, Giovanni Dialetto, Zeina Kanafani, Antonio Toniolo, Suzana Bukovski, Christy C. Dixon, Tatiana Vinogradova, Jorge Thierer, Souha S. Kanj, Vinod Thomas, Daniel J. Sexton, Vance G. Fowler, Andrew M. Morris, S. Athanasia, Ren Tan, Carlos Cervera, Chirouze, C, Alla, F, Fowler VG, Jr, Sexton, Dj, Corey, Gr, Chu, Vh, Wang, A, Erpelding, Ml, DURANTE MANGONI, Emanuele, Fernández Hidalgo, N, Giannitsioti, E, Hannan, Mm, Lejko Zupanc, T, Miró, Jm, Muñoz, P, Murdoch, Dr, Tattevin, P, Tribouilloy, C, Hoen, B., Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), Service des maladies infectieuses et tropicales, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, Duke University Medical Center, Monaldi Hospital, Mater Hospitals, University Medical Center Ljubljana, Institut d'Investigacions Biomèdiques August Pi i Sunyer ( IDIBAPS ), Universitat de Barcelona ( UB ), Clinical Microbiology and Infectious Diseases Department, Universidad Complutense de Madrid [Madrid] ( UCM ), Department of Pathology, University of Otago, Microbiology Unit, Canterbury Health Laboratories, Service des maladies infectieuses et réanimation médicale, Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Pontchaillou, Mécanismes physiologiques et conséquences des calcifications cardiovasculaires: rôle des remodelages cardiovasculaires et osseux, Université de Picardie Jules Verne ( UPJV ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), CHU Pointe-à-Pitre/Abymes [Guadeloupe], Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Universidad Complutense de Madrid = Complutense University of Madrid [Madrid] (UCM), University of Otago [Dunedin, Nouvelle-Zélande], Service des maladies infectieuses et réanimation médicale [Rennes] = Infectious Disease and Intensive Care [Rennes], CHU Pontchaillou [Rennes], Université de Picardie Jules Verne (UPJV)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Saint-Jacques, Service des maladies infectieuses et réanimation médicale [Rennes], Hôpital Pontchaillou-Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)
- Subjects
Male ,diagnosis ,International Cooperation ,Medizin ,blood culture ,Cohort Studies ,surgery ,[ SDV.MP ] Life Sciences [q-bio]/Microbiology and Parasitology ,Prospective Studies ,Prospective cohort study ,Endocarditis ,Mortality rate ,heart valve ,Middle Aged ,Staphylococcal Infections ,Heart Valves ,prosthetic valve ,3. Good health ,Treatment Outcome ,Infectious Diseases ,[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology ,Infective endocarditis ,Cohort ,endocarditis ,Female ,Cohort study ,Adult ,Microbiology (medical) ,Staphylococcus aureus ,medicine.medical_specialty ,Endocarditis, Staphylococcus aureus, heart valve, combined treatment, blood culture, clinical microbiology, etiology, diagnosis ,Prosthesis-Related Infections ,etiology ,Staphylococcal infections ,Internal medicine ,[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology ,1-year mortality ,Prosthetic valve ,Surgery ,Aged ,Humans ,Survival Analysis ,medicine ,combined treatment ,clinical microbiology ,Proportional hazards model ,business.industry ,medicine.disease ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
International audience; Background - The impact of early valve surgery (EVS) on the outcome of Staphylococcus aureus (SA) prosthetic valve infective endocarditis (PVIE) is unresolved. The objective of this study was to evaluate the association between EVS, performed within the first 60 days of hospitalization, and outcome of SA PVIE within the International Collaboration on Endocarditis-Prospective Cohort Study. Methods - Participants were enrolled between June 2000 and December 2006. Cox proportional hazards modeling that included surgery as a time-dependent covariate and propensity adjustment for likelihood to receive cardiac surgery was used to evaluate the impact of EVS and 1-year all-cause mortality on patients with definite left-sided S. aureus PVIE and no history of injection drug use. Results - EVS was performed in 74 of the 168 (44.3%) patients. One-year mortality was significantly higher among patients with S. aureus PVIE than in patients with non-S. aureus PVIE (48.2% vs 32.9%; P = .003). Staphylococcus aureus PVIE patients who underwent EVS had a significantly lower 1-year mortality rate (33.8% vs 59.1%; P = .001). In multivariate, propensity-adjusted models, EVS was not associated with 1-year mortality (risk ratio, 0.67 [95% confidence interval, .39-1.15]; P = .15). Conclusions - In this prospective, multinational cohort of patients with S. aureus PVIE, EVS was not associated with reduced 1-year mortality. The decision to pursue EVS should be individualized for each patient, based upon infection-specific characteristics rather than solely upon the microbiology of the infection causing PVIE.
- Published
- 2015
- Full Text
- View/download PDF
22. Genotypic diversity of coagulase-negative staphylococci causing endocarditis: a global perspective
- Author
-
Cathy A. Petti, Efthymia Giannitsioti, Dannah Wray, Bruno Hoen, Tony M. Korman, Emilio Bouza, Thanh Doco-Lecompte, Jerome J. Federspiel, Patrick Plésiat, Riccardo Utili, L. Barth Reller, Eugene Athan, Arthur J. Morris, David R. Murdoch, Suzanne F. Bradley, Suzanne Ryan, José M. Miró, Annibale Raglio, Francesca Tripodi, Francesc Marco, Christopher W. Woods, K. Boisson, Vivian H. Chu, Porl Reinbott, Cristina Garcia-de-la-Maria, David L. Gordon, Selwyn Lang, Keith E. Simmon, Vance G. Fowler, Suzana Bukovski, Service des maladies infectieuses et tropicales, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, Agents pathogènes et inflammation - UFC (EA 4266) (API), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), Agents pathogènes et inflammation - UFC (EA 4266) ( API ), Université de Franche-Comté ( UFC ), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Petti, Ca, Simmon, Ke, Miro, Jm, Hoen, B, Marco, F, Chu, Vh, Athan, E, Bukovski, S, Bouza, E, Bradley, S, Fowler, Vg, Giannitsioti, E, Gordon, D, Reinbott, P, Korman, T, Lang, S, DE LA MARIA, Cg, Raglio, A, Morris, Aj, Plesiat, P, Ryan, S, DOCO LECOMPTE, T, Tripodi, F, Utili, Riccardo, Wray, D, Federspiel, Jj, Boisson, K, Reller, Lb, Murdoch, Dr, Woods, Cw, and THE ICE MICRO, Investigators
- Subjects
MESH: Sequence Analysis, DNA ,Epidemiology ,MESH : Polymorphism, Genetic ,Staphylococcus ,MESH : Aged ,MESH : Coagulase ,Sequence Homology ,MESH : Genotype ,MESH: Genotype ,endocarditis ,coagulase-negative staphylococci ,DNA target sequencing ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Genotype ,MESH : DNA, Ribosomal ,MESH : DNA, Bacterial ,MESH: Sequence Homology ,MESH : Anti-Bacterial Agents ,MESH : Endocarditis, Bacterial ,MESH: Phylogeny ,Phylogeny ,Genetics ,MESH: Aged ,0303 health sciences ,MESH: Microbial Sensitivity Tests ,MESH: Middle Aged ,MESH: DNA, Ribosomal ,MESH: Staphylococcus ,DNA-Directed RNA Polymerases ,Middle Aged ,3. Good health ,Anti-Bacterial Agents ,Bacterial Typing Techniques ,[ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Infective endocarditis ,Coagulase ,MESH: Coagulase ,Microbiology (medical) ,DNA, Bacterial ,Sequence analysis ,Microbial Sensitivity Tests ,Biology ,Peptide Elongation Factor Tu ,DNA, Ribosomal ,MESH: Bacterial Typing Techniques ,Microbiology ,Bacterial genetics ,03 medical and health sciences ,MESH : Sequence Homology ,MESH : DNA-Directed RNA Polymerases ,MESH: Anti-Bacterial Agents ,MESH: Peptide Elongation Factor Tu ,MESH: Polymorphism, Genetic ,medicine ,Endocarditis ,Humans ,MESH : Middle Aged ,MESH: Endocarditis, Bacterial ,030304 developmental biology ,Aged ,MESH : Staphylococcus ,Genetic diversity ,Polymorphism, Genetic ,MESH: Humans ,030306 microbiology ,MESH : Humans ,MESH : Phylogeny ,Endocarditis, Bacterial ,Sequence Analysis, DNA ,medicine.disease ,rpoB ,MESH: DNA, Bacterial ,[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology ,MESH: DNA-Directed RNA Polymerases ,MESH : Bacterial Typing Techniques ,MESH : Microbial Sensitivity Tests ,MESH : Peptide Elongation Factor Tu ,MESH : Sequence Analysis, DNA - Abstract
Coagulase-negative staphylococci (CNS) are important causes of infective endocarditis (IE), but their microbiological profiles are poorly described. We performed DNA target sequencing and susceptibility testing for 91 patients with definite CNS IE who were identified from the International Collaboration on Endocarditis—Microbiology, a large, multicenter, multinational consortium. A hierarchy of gene sequences demonstrated great genetic diversity within CNS from patients with definite endocarditis that represented diverse geographic regions. In particular, rpoB sequence data demonstrated unique genetic signatures with the potential to serve as an important tool for global surveillance.
- Published
- 2008
- Full Text
- View/download PDF
23. Candida infective endocarditis
- Author
-
Pilar Tornos, Denis Spelman, Donald P. Levine, Paul A. Pappas, Tom S.J. Elliott, John L Klein, Liliana Clara, Stamatios Lerakis, José M. Miró, Emilio Bouza, John W. Baddley, Vance G. Fowler, Ethan Rubinstein, Daniel K. Benjamin, Bruno Baršić, Christopher H. Cabell, Eugene Athan, Arthur J. Morris, Mukesh Patel, Zeina A. Kanafani, Vivian H. Chu, Baddley, Jw, Benjamin DK, Jr, Patel, M, Miró, J, Athan, E, Barsic, B, Bouza, E, Clara, L, Elliott, T, Kanafani, Z, Klein, J, Lerakis, S, Levine, D, Spelman, D, Rubinstein, E, Tornos, P, Morris, Aj, Pappas, P, Fowler VG, Jr, Chu, Vh, Cabell, C, among International Collaboration on Endocarditis Prospective Cohort Study, Group, Utili, Riccardo, AII - Amsterdam institute for Infection and Immunity, Infectious diseases, Hewlett-Packard Laboratories [Bangalore], Hewlett-Packard, Institut de médecine moléculaire de Rangueil (I2MR), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-IFR150-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université Fédérale Toulouse Midi-Pyrénées
- Subjects
Male ,MESH: Endocarditis ,Antifungal Agents ,chemistry.chemical_compound ,0302 clinical medicine ,Catheters, Indwelling ,MESH: Risk Factors ,Risk Factors ,Amphotericin B ,Epidemiology ,030212 general & internal medicine ,Candida ,MESH: Aged ,0303 health sciences ,Cross Infection ,MESH: Middle Aged ,Endocarditis ,Candidiasis ,General Medicine ,Prostheses and Implants ,Middle Aged ,MESH: Candidiasis ,3. Good health ,Infectious Diseases ,Infective endocarditis ,Female ,medicine.drug ,Microbiology (medical) ,Adult ,medicine.medical_specialty ,MESH: Prostheses and Implants ,MESH: Catheters, Indwelling ,Article ,03 medical and health sciences ,MESH: Candida ,Internal medicine ,medicine ,infective endocarditis ,Candida spp ,Humans ,Mycosis ,Aged ,Voriconazole ,MESH: Humans ,030306 microbiology ,business.industry ,MESH: Cross Infection ,MESH: Adult ,MESH: Antifungal Agents ,medicine.disease ,[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology ,MESH: Male ,Surgery ,chemistry ,Caspofungin ,business ,MESH: Female ,Fluconazole - Abstract
International audience; Candida infective endocarditis (IE) is uncommon but often fatal. Most epidemiologic data are derived from small case series or case reports. This study was conducted to explore the epidemiology, treatment patterns, and outcomes of patients with Candida IE. We compared 33 Candida IE cases to 2,716 patients with non-fungal IE in the International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS). Patients were enrolled and the data collected from June 2000 until August 2005. We noted that patients with Candida IE were more likely to have prosthetic valves (p < 0.001), short-term indwelling catheters (p < 0.0001), and have healthcare-associated infections (p < 0.001). The reasons for surgery differed between the two groups: myocardial abscess (46.7% vs. 22.2%, p = 0.026) and persistent positive blood cultures (33.3% vs. 9.9%, p = 0.003) were more common among those with Candida IE. Mortality at discharge was higher in patients with Candida IE (30.3%) when compared to non-fungal cases (17%, p = 0.046). Among Candida patients, mortality was similar in patients who received combination surgical and antifungal therapy versus antifungal therapy alone (33.3% vs. 27.8%, p = 0.26). New antifungal drugs, particularly echinocandins, were used frequently. These multi-center data suggest distinct epidemiologic features of Candida IE when compared to non-fungal cases. Indications for surgical intervention are different and mortality is increased. Newer antifungal treatment options are increasingly used. Large, multi-center studies are needed to help better define Candida IE.
- Published
- 2008
- Full Text
- View/download PDF
24. Cardiovascular Implantable Electronic Device Infections: A Contemporary Review.
- Author
-
Bielick CG, Arnold CJ, and Chu VH
- Subjects
- Humans, Risk Factors, Prosthesis-Related Infections therapy, Prosthesis-Related Infections diagnosis, Prosthesis-Related Infections epidemiology, Prosthesis-Related Infections prevention & control, Defibrillators, Implantable adverse effects, Pacemaker, Artificial adverse effects, Pacemaker, Artificial microbiology
- Abstract
Infections associated with cardiac implantable electronic devices (CIEDs) are increasing and are a cause of significant morbidity and mortality. This article summarizes the latest updates with respect to the epidemiology, microbiology, and risk factors for CIED-related infections. It also covers important considerations regarding the diagnosis, management, and prevention of these infections. Newer technologies such as leadless pacemakers and subcutaneous implantable cardioverters and defibrillators are discussed., Competing Interests: Disclosure C. Bielick: there are no competing interests, personal financial interests, or other competing interests. Funding support was through the National Institute of Allergy and Infectious Diseases, United States at the National Institutes of Health (grant number T32 AI007046 to C.B.) while employed at the University of Virginia Division of Infectious Diseases and International Health. Christopher Arnold: there are no competing interests, personal financial interests, or other competing interests. Vivian Chu: UpToDate contributor., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
25. Device-Related Infections: Evolving Strategies for a Universal Problem.
- Author
-
Chu VH
- Abstract
Competing Interests: Disclosure The author discloses writing for UpToDate. No other disclosures.
- Published
- 2024
- Full Text
- View/download PDF
26. Long-term Risk of Serious Infections and Mortality Among Patients Surviving Drug Use-Associated Infective Endocarditis.
- Author
-
Figgatt MC, Rosen DL, Chu VH, Wu LT, and Schranz AJ
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Risk Factors, Hospitalization statistics & numerical data, Bacteremia mortality, Endocarditis, Bacterial mortality, Aged, Cohort Studies, Substance-Related Disorders complications, Substance-Related Disorders mortality, Endocarditis mortality
- Abstract
Among a statewide cohort of 1874 patients surviving hospitalization for drug use-associated endocarditis during 2017-2020, the 3-year risk of death or future hospitalization was 38% (16% for death before later infection, 14% for recurrent endocarditis, 14% for soft tissue, 9% for bacteremia, 5% for bone/joint, and 4% for spinal infections)., Competing Interests: Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
27. Welcoming Discourse on the Approach for Gram-Negative Bacteremia and Candidemia in Cardiovascular Implantable Electronic Device Infections.
- Author
-
Bourque JM, Chu VH, Mason PK, Schaller RD, Woolley AE, and Dorbala S
- Published
- 2024
- Full Text
- View/download PDF
28. 18 F-FDG PET/CT and Radiolabeled Leukocyte SPECT/CT Imaging for the Evaluation of Cardiovascular Infection in the Multimodality Context: ASNC Imaging Indications (ASNC I 2 ) Series Expert Consensus Recommendations From ASNC, AATS, ACC, AHA, ASE, EANM, HRS, IDSA, SCCT, SNMMI, and STS.
- Author
-
Bourque JM, Birgersdotter-Green U, Bravo PE, Budde RPJ, Chen W, Chu VH, Dilsizian V, Erba PA, Gallegos Kattan C, Habib G, Hyafil F, Khor YM, Manlucu J, Mason PK, Miller EJ, Moon MR, Parker MW, Pettersson G, Schaller RD, Slart RHJA, Strom JB, Wilkoff BL, Williams A, Woolley AE, Zwischenberger BA, and Dorbala S
- Subjects
- Humans, Algorithms, Cardiovascular Infections diagnostic imaging, Endocarditis diagnostic imaging, Prognosis, Prosthesis-Related Infections diagnostic imaging, Reproducibility of Results, Consensus, Delphi Technique, Fluorodeoxyglucose F18 administration & dosage, Leukocytes, Positron Emission Tomography Computed Tomography standards, Predictive Value of Tests, Radiopharmaceuticals administration & dosage, Single Photon Emission Computed Tomography Computed Tomography standards
- Abstract
This document on cardiovascular infection, including infective endocarditis, is the first in the American Society of Nuclear Cardiology Imaging Indications (ASNC I
2 ) series to assess the role of radionuclide imaging in the multimodality context for the evaluation of complex systemic diseases with multisocietal involvement including pertinent disciplines. A rigorous modified Delphi approach was used to determine consensus clinical indications, diagnostic criteria, and an algorithmic approach to diagnosis of cardiovascular infection including infective endocarditis. Cardiovascular infection incidence is increasing and is associated with high morbidity and mortality. Current strategies based on clinical criteria and an initial echocardiographic imaging approach are effective but often insufficient in complicated cardiovascular infection. Radionuclide imaging with fluorine-18 fluorodeoxyglucose (18 F-FDG) positron emission tomography/computed tomography (CT) and single photon emission computed tomography/CT leukocyte scintigraphy can enhance the evaluation of suspected cardiovascular infection by increasing diagnostic accuracy, identifying extracardiac involvement, and assessing cardiac implanted device pockets, leads, and all portions of ventricular assist devices. This advanced imaging can aid in key medical and surgical considerations. Consensus diagnostic features include focal/multifocal or diffuse heterogenous intense18 F-FDG uptake on valvular and prosthetic material, perivalvular areas, device pockets and leads, and ventricular assist device hardware persisting on non-attenuation corrected images. There are numerous clinical indications with a larger role in prosthetic valves, and cardiac devices particularly with possible infective endocarditis or in the setting of prior equivocal or non-diagnostic imaging. Illustrative cases incorporating these consensus recommendations provide additional clarification. Future research is necessary to refine application of these advanced imaging tools for surgical planning, to identify treatment response, and more., (Copyright © 2024 by the American Society of Nuclear Cardiology, the American College of Cardiology, Heart Rhythm Society, and the Infectious Diseases Society of America. Published by Elsevier on behalf of the American Society of Nuclear Cardiology, the American College of Cardiology, Heart Rhythm Society, and by Oxford University Press on behalf of the Infectious Diseases Society of America. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
29. 18F-FDG PET/CT and radiolabeled leukocyte SPECT/CT imaging for the evaluation of cardiovascular infection in the multimodality context: ASNC Imaging Indications (ASNC I2) Series Expert Consensus Recommendations from ASNC, AATS, ACC, AHA, ASE, EANM, HRS, IDSA, SCCT, SNMMI, and STS.
- Author
-
Bourque JM, Birgersdotter-Green U, Bravo PE, Budde RPJ, Chen W, Chu VH, Dilsizian V, Erba PA, Gallegos Kattan C, Habib G, Hyafil F, Khor YM, Manlucu J, Mason PK, Miller EJ, Moon MR, Parker MW, Pettersson G, Schaller RD, Slart RHJA, Strom JB, Wilkoff BL, Williams A, Woolley AE, Zwischenberger BA, and Dorbala S
- Abstract
This document on cardiovascular infection, including infective endocarditis, is the first in the American Society of Nuclear Cardiology Imaging Indications (ASNC I2) series to assess the role of radionuclide imaging in the multimodality context for the evaluation of complex systemic diseases with multi-societal involvement including pertinent disciplines. A rigorous modified Delphi approach was used to determine consensus clinical indications, diagnostic criteria, and an algorithmic approach to diagnosis of cardiovascular infection including infective endocarditis. Cardiovascular infection incidence is increasing and is associated with high morbidity and mortality. Current strategies based on clinical criteria and an initial echocardiographic imaging approach are effective but often insufficient in complicated cardiovascular infection. Radionuclide imaging with 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) and single photon emission computed tomography/CT leukocyte scintigraphy can enhance the evaluation of suspected cardiovascular infection by increasing diagnostic accuracy, identifying extracardiac involvement, and assessing cardiac implanted device pockets, leads, and all portions of ventricular assist devices. This advanced imaging can aid in key medical and surgical considerations. Consensus diagnostic features include focal/multi-focal or diffuse heterogenous intense 18F-FDG uptake on valvular and prosthetic material, perivalvular areas, device pockets and leads, and ventricular assist device hardware persisting on non-attenuation corrected images. There are numerous clinical indications with a larger role in prosthetic valves, and cardiac devices particularly with possible infective endocarditis or in the setting of prior equivocal or non-diagnostic imaging. Illustrative cases incorporating these consensus recommendations provide additional clarification. Future research is necessary to refine application of these advanced imaging tools for surgical planning, to identify treatment response, and more., (© 2024 The American Society of Nuclear Cardiology, The American College of Cardiology, Heart Rhythm Society, and the Infectious Disease Society of America. Published by Elsevier on behalf of the American Society of Nuclear Cardiology, the American College of Cardiology, Heart Rhythm Society, and by Oxford University Press on behalf of the Infectious Disease Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
30. Update on Cardiovascular Implantable Electronic Device Infections and Their Prevention, Diagnosis, and Management: A Scientific Statement From the American Heart Association: Endorsed by the International Society for Cardiovascular Infectious Diseases.
- Author
-
Baddour LM, Esquer Garrigos Z, Rizwan Sohail M, Havers-Borgersen E, Krahn AD, Chu VH, Radke CS, Avari-Silva J, El-Chami MF, Miro JM, and DeSimone DC
- Subjects
- United States, Humans, American Heart Association, Communicable Diseases diagnosis, Communicable Diseases epidemiology, Communicable Diseases therapy, Endocarditis, Bacterial drug therapy, Cardiovascular Infections, Cardiology, Defibrillators, Implantable adverse effects
- Abstract
The American Heart Association sponsored the first iteration of a scientific statement that addressed all aspects of cardiovascular implantable electronic device infection in 2010. Major advances in the prevention, diagnosis, and management of these infections have occurred since then, necessitating a scientific statement update. An 11-member writing group was identified and included recognized experts in cardiology and infectious diseases, with a career focus on cardiovascular infections. The group initially met in October 2022 to develop a scientific statement that was drafted with front-line clinicians in mind and focused on providing updated clinical information to enhance outcomes of patients with cardiovascular implantable electronic device infection. The current scientific statement highlights recent advances in prevention, diagnosis, and management, and how they may be incorporated in the complex care of patients with cardiovascular implantable electronic device infection.
- Published
- 2024
- Full Text
- View/download PDF
31. A high-performance method for quantitation of aflatoxins B1, B2, G1, G2: Full validation for raisin, peanut matrices, and survey of related products at Ho Chi Minh City.
- Author
-
Nguyen TD, Nguyen TNH, Ly TK, Nguyen QH, Le TT, Chu VH, Nguyen TD, and Le DV
- Abstract
Optimization and validation for simultaneous quantitation of four aflatoxins B1, B2, G1, and G2 in peanuts and raisins were performed on ultra-performance liquid chromatography in a combination of fluorescence detector, without derivatization. The advantages were short analysis time, simple sample handling, and reduced solvent consumption. Instrument detection limits of AFB1, AFB2, AFG1, and AFG2 were 0.07, 0.01, 0.1, and 0.008 μg/kg, respectively, lower than those obtained by LCMSMS and HPLC-FLD with derivatization. Two solvent mixtures were chosen for two different matrices whose matrix effect was not negligible (2.81%-8.04% for peanuts and 5.63%-11.43% for raisins). The linear ranges were from 0.2 to 20 μg/L for AFB1 and AFG1 and from 0.05 to 5 μg/L for AFB2 and AFG2. The limits of detection and quantification were 0.025-0.1 and 0.075-0.3 μg/kg for peanuts and raisins, respectively. Recoveries at three other concentrations from 0.75 to 125 μg/kg of total aflatoxins were obtained between 76.5% and 99.8% (with RSD < 6%) following the SANTE 11312/2021 . Validation parameters complied with the requirements of ISO/IEC 17025:2017. The extracts and the sample could be stabilized at 4°C and 20°C for 24 h and at -20°C for up to 21 days, respectively. Thus, the study can be used as a standard method for the analysis of Aflatoxins (AFs) in peanut and raisin matrices. Investigation of 350 peanut samples collected at Markets in the central districts of HCM city showed that 28.6% were contaminated with AFB1 from 0.31 up to 554 μg/kg; 13.4% contained AFB2, and 5.7% of AFG1 in the range of 0.4-53 μg/kg and 0.4-9.57 μg/kg, respectively; AFG2 (about 0.6%) was detected from 0.45 to 0.75 μg/kg. Meanwhile, 12.8% exceeded the total aflatoxins limit, and 13.4% exceeded the AFB1 limit. AFs were almost not found in the 350 raisin samples., (© 2023 The Authors. Food Science & Nutrition published by Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
32. The Impact of Discharge Against Medical Advice on Readmission After Opioid Use Disorder-Associated Infective Endocarditis: a National Cohort Study.
- Author
-
Schranz AJ, Tak C, Wu LT, Chu VH, Wohl DA, and Rosen DL
- Subjects
- Female, Humans, Cohort Studies, Patient Discharge, Patient Readmission, Retrospective Studies, Male, Endocarditis epidemiology, Endocarditis, Bacterial complications, Opioid-Related Disorders epidemiology, Opioid-Related Disorders therapy, Opioid-Related Disorders complications
- Abstract
Background: Hospitalizations for infective endocarditis (IE) associated with opioid use disorder (O-IE) have increased in the USA and have been linked to high rates of discharge against medical advice (DAMA). DAMA represents a truncation of care for a severe infection, yet patient outcomes after DAMA are unknown., Objective: This study aimed to assess readmissions following O-IE and quantify the impact of DAMA on outcomes., Design: A retrospective study of a nationally representative dataset of persons' inpatient discharges in the USA in 2016 PARTICIPANTS: A total of 6018 weighted persons were discharged for O-IE, stratified by DAMA vs. other discharge statuses. Of these, 1331 (22%) were DAMA., Main Measures: The primary outcome of interest was 30-day readmission rates, stratified by discharge type. We also examined the total number of hospitalizations during the year and estimated the effect of DAMA on readmission., Key Results: Compared with non-DAMA, those experiencing DAMA were more commonly female, resided in metropolitan areas, lower income, and uninsured. Crude 30-day readmission following DAMA was 50%, compared with 21% for other discharge types. DAMA was strongly associated with readmission in an adjusted logistic regression model (OR 3.72, CI 3.02-4.60). Persons experiencing DAMA more commonly had ≥2 more hospitalizations during the period (31% vs. 18%, p<0.01), and were less frequently readmitted at the same hospital (49% vs 64%, p<0.01)., Conclusions: DAMA occurs in nearly a quarter of patients hospitalized for O-IE and is strongly associated with short-term readmission. Interventions to address the root causes of premature discharges will enhance O-IE care, reduce hospitalizations and improve outcomes., (© 2022. The Author(s), under exclusive licence to Society of General Internal Medicine.)
- Published
- 2023
- Full Text
- View/download PDF
33. Phonon transport in Janus monolayer siblings: a comparison of 1T and 2H-ISbTe.
- Author
-
Chu VH, Le TH, Pham TT, and Nguyen DL
- Abstract
In the last decade, two-dimension materials with reduced symmetry have attracted a lot of attention due to the emerging quantum features induced by their structural asymmetry. Two-dimensional Janus materials, named after the Roman deity of beginnings and endings who has two faces, have a structure with broken mirror symmetry because the two sides of the material have distinct chemical compositions. Extensive study has been undertaken on phonon transport for Janus monolayers for their strong applicability in thermoelectrics compared to their parent material, while Janus materials with the same space group but a distinct crystal protype have received very little attention. Using first-principles calculations and the Boltzmann transport equation accelerated by a machine learning interatomic potential, we explore the phonon transport of 1T and 2H-ISbTe. ISbTe possesses significant intrinsic phonon-phonon interactions, resulting in a low lattice thermal conductivity, as a result of its covalent bonding and low elastic constants. A thorough examination of phonon group velocity, phonon lifetime, and heat carrier identification reveals that 2H has a low lattice thermal conductivity of 1.5 W mK
-1 , which is 2.3 times lower than its 1T sibling. This study demonstrates Janus ISbTe monolayers have extensive physical phenomena in their thermal transport characteristics, which might provide a new degree of control over their thermal conductivity for applications such as thermal management and thermoelectric devices., Competing Interests: The authors declare that they have no conflict of interest., (This journal is © The Royal Society of Chemistry.)- Published
- 2023
- Full Text
- View/download PDF
34. Clinical characteristics and outcome of infective endocarditis due to Abiotrophia and Granulicatella compared to Viridans group streptococci.
- Author
-
Téllez A, Ambrosioni J, Hernández-Meneses M, Llopis J, Ripa M, Chambers ST, Holland D, Almela M, Fernández-Hidalgo N, Almirante B, Bouza E, Strahilevitz J, Hannan MM, Harkness J, Kanafani ZA, Lalani T, Lang S, Raymond N, Read K, Vinogradova T, Woods CW, Wray D, Moreno A, Chu VH, and Miro JM
- Subjects
- Hospital Mortality, Humans, Middle Aged, Prospective Studies, Viridans Streptococci, Abiotrophia, Endocarditis drug therapy, Endocarditis, Bacterial drug therapy
- Abstract
Objective: To describe the clinical characteristics and outcome of Abiotrophia and Granulicatella infective endocarditis and compare them with Viridans group streptococci infective endocarditis., Methods: All patients in the International Collaboration on Endocarditis (ICE) - prospective cohort study (PCS) and the ICE-PLUS cohort were included (n = 8112). Data from patients with definitive or possible IE due to Abiotrophia species, Granulicatella species and Viridans group streptococci was analyzed. A propensity score (PS) analysis comparing the ABI/GRA-IE and VGS-IE groups according to a 1:2 ratio was performed., Results: Forty-eight (0.64%) cases of ABI/GRA-IE and 1,292 (17.2%) VGS-IE were included in the analysis. The median age of patients with ABI/GRA-IE was lower than VGS-IE (48.1 years vs. 57.9 years; p = 0.001). Clinical features and the rate of in-hospital surgery was similar between ABI/GRA-IE and VGS-IE (52.1% vs. 45.4%; p = 0.366). Unadjusted in-hospital death was lower in ABI/GRA-IE than VGS-IE (2.1% vs. 8.8%; p = 0.003), and cumulative six-month mortality was lower in ABI/GRA-IE than VGS-IE (2.1% vs. 11.9%; p<0.001). After PS analysis, in-hospital mortality was similar in both groups, but six-month mortality was lower in the ABI/GRA IE group (2.1% vs. 10.4%; p = 0.029)., Conclusions: Patients with ABI/GRA-IE were younger, had similar clinical features and rates of surgery and better prognosis than VGS-IE., (Copyright © 2022 The British Infection Association. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
35. Infective Endocarditis in Patients on Chronic Hemodialysis.
- Author
-
Pericàs JM, Llopis J, Jiménez-Exposito MJ, Kourany WM, Almirante B, Carosi G, Durante-Mangoni E, Fortes CQ, Giannitsioti E, Lerakis S, Montagna-Mella R, Ambrosioni J, Tan RS, Mestres CA, Wray D, Pachirat O, Moreno A, Chu VH, de Lazzari E, Fowler VG Jr, and Miró JM
- Subjects
- Aged, Anti-Bacterial Agents therapeutic use, Cardiac Surgical Procedures, Cohort Studies, Endocarditis drug therapy, Endocarditis surgery, Female, Humans, Kidney Failure, Chronic complications, Kidney Failure, Chronic therapy, Male, Methicillin-Resistant Staphylococcus aureus, Middle Aged, Staphylococcal Infections drug therapy, Staphylococcal Infections etiology, Staphylococcal Infections mortality, Staphylococcal Infections surgery, Arteriovenous Shunt, Surgical adverse effects, Catheters, Indwelling adverse effects, Endocarditis etiology, Endocarditis mortality, Renal Dialysis adverse effects
- Abstract
Background: Infective endocarditis (IE) is a common and serious complication in patients receiving chronic hemodialysis (HD)., Objectives: This study sought to investigate whether there are significant differences in complications, cardiac surgery, relapses, and mortality between IE cases in HD and non-HD patients., Methods: Prospective cohort study (International Collaboration on Endocarditis databases, encompassing 7,715 IE episodes from 2000 to 2006 and from 2008 to 2012). Descriptive analysis of baseline characteristics, epidemiological and etiological features, complications and outcomes, and their comparison between HD and non-HD patients was performed. Risk factors for major embolic events, cardiac surgery, relapses, and in-hospital and 6-month mortality were investigated in HD-patients using multivariable logistic regression., Results: A total of 6,691 patients were included and 553 (8.3%) received HD. North America had a higher HD-IE proportion than the other regions. The predominant microorganism was Staphylococcus aureus (47.8%), followed by enterococci (15.4%). Both in-hospital and 6-month mortality were significantly higher in HD versus non-HD-IE patients (30.4% vs. 17% and 39.8% vs. 20.7%, respectively; p < 0.001). Cardiac surgery was less frequently performed among HD patients (30.6% vs. 46.2%; p < 0.001), whereas relapses were higher (9.4% vs. 2.7%; p < 0.001). Risk factors for 6-month mortality included Charlson score (hazard ratio [HR]: 1.26; 95% confidence interval [CI]: 1.11 to 1.44; p = 0.001), CNS emboli and other emboli (HR: 3.11; 95% CI: 1.84 to 5.27; p < 0.001; and HR: 1.73; 95% CI: 1.02 to 2.93; p = 0.04, respectively), persistent bacteremia (HR: 1.79; 95% CI: 1.11 to 2.88; p = 0.02), and acute onset heart failure (HR: 2.37; 95% CI: 1.49 to 3.78; p < 0.001)., Conclusions: HD-IE is a health care-associated infection chiefly caused by S. aureus, with increasing rates of enterococcal IE. Mortality and relapses are very high and significantly larger than in non-HD-IE patients, whereas cardiac surgery is less frequently performed., Competing Interests: Funding Support and Author Disclosures This study was supported by the National Institutes of Health (AI-059111 [to Dr. Fowler], Red Española de Investigación en Patología Infecciosa (V–2003-REDC14A-O [to Dr. Miró], and Instituto de Salud Carlos III (FIS 00-0475 [to Dr. Miró]). Dr. Miró received a personal 80:20 research grant from the Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain, during 2017 to 2019. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
36. Prospective Cohort Study of Infective Endocarditis in People Who Inject Drugs.
- Author
-
Pericàs JM, Llopis J, Athan E, Hernández-Meneses M, Hannan MM, Murdoch DR, Kanafani Z, Freiberger T, Strahilevitz J, Fernández-Hidalgo N, Lamas C, Durante-Mangoni E, Tattevin P, Nacinovich F, Chu VH, and Miró JM
- Subjects
- Adult, Aged, Endocarditis epidemiology, Female, Follow-Up Studies, Global Health, Humans, Incidence, Male, Middle Aged, Prospective Studies, Risk Factors, Substance Abuse, Intravenous epidemiology, Endocarditis etiology, Risk Assessment methods, Substance Abuse, Intravenous complications
- Abstract
Background: Infective endocarditis (IE) in people who inject drugs (PWID) is an emergent public health problem., Objectives: The purpose of this study was to investigate IE in PWID and compare it with IE in non-PWID patients., Methods: Two prospective cohort studies (ICE-PCS and ICE-Plus databases, encompassing 8,112 IE episodes from 2000 to 2006 and 2008 to 2012, with 64 and 34 sites and 28 and 18 countries, respectively). Outcomes were compared between PWID and non-PWID patients with IE. Logistic regression analyses were performed to investigate risk factors for 6-month mortality and relapses amongst PWID., Results: A total of 7,616 patients (591 PWID and 7,025 non-PWID) were included. PWID patients were significantly younger (median 37.0 years [interquartile range: 29.5 to 44.2 years] vs. 63.3 years [interquartile range: 49.3 to 74.0 years]; p < 0.001), male (72.5% vs. 67.4%; p = 0.007), and presented lower rates of comorbidities except for human immunodeficiency virus, liver disease, and higher rates of prior IE. Amongst IE cases in PWID, 313 (53%) episodes involved left-side valves and 204 (34.5%) were purely left-sided IE. PWID presented a larger proportion of native IE (90.2% vs. 64.4%; p < 0.001), whereas prosthetic-IE and cardiovascular implantable electronic device-IE were more frequent in non-PWID (9.3% vs. 27.0% and 0.5% vs. 8.6%; both p < 0.001). Staphylococcus aureus caused 65.9% and 26.8% of cases in PWID and non-PWID, respectively (p < 0.001). PWID presented higher rates of systemic emboli (51.1% vs. 22.5%; p < 0.001) and persistent bacteremia (14.7% vs. 9.3%; p < 0.001). Cardiac surgery was less frequently performed (39.5% vs. 47.8%; p < 0.001), and in-hospital and 6-month mortality were lower in PWID (10.8% vs. 18.2% and 14.4% vs. 22.2%; both p < 0.001), whereas relapses were more frequent in PWID (9.5% vs. 2.8%; p < 0.001). Prior IE, left-sided IE, polymicrobial etiology, intracardiac complications, and stroke were risk factors for 6-month mortality, whereas cardiac surgery was associated with lower mortality in the PWID population., Conclusions: A notable proportion of cases in PWID involve left-sided valves, prosthetic valves, or are caused by microorganisms other than S. aureus., Competing Interests: Funding Support and Author Disclosures This study was supported by the Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (# E26/202.782/2015 to Dr. Lamas), Red Española de Investigación en Patología Infecciosa (V-2003-REDC14A-O), and Fondo de Investigaciones Sanitarias de la Seguridad Social (FIS 00-0475) (Dr. Miro). Dr. Miro has received a personal 80:20 research grant from the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, for 2017 to 2021. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
37. Baseline assessment of microplastic concentrations in marine and freshwater environments of a developing Southeast Asian country, Viet Nam.
- Author
-
Strady E, Dang TH, Dao TD, Dinh HN, Do TTD, Duong TN, Duong TT, Hoang DA, Kieu-Le TC, Le TPQ, Mai H, Trinh DM, Nguyen QH, Tran-Nguyen QA, Tran QV, Truong TNS, Chu VH, and Vo VC
- Subjects
- Cities, Environmental Monitoring, Geologic Sediments, Humans, Plastics, Rivers, Vietnam, Microplastics, Water Pollutants, Chemical analysis
- Abstract
In aquatic environments, assessment of microplastic concentrations is increasing worldwide but environments from developing countries remain under-evaluated. Due to disparities of facilities, financial resources and human resources between countries, protocols of sampling, analysis and observations used in developed countries cannot be fully adapted in developing ones, and required specific adaptations. In Viet Nam, an adapted methodology was developed and commonly adopted by local researchers to implement a microplastic monitoring in sediments and surface waters of 21 environments (rivers, lakes, bays, beaches) of eight cities or provinces. Microplastic concentrations in surface waters varied from 0.35 to 2522 items m-3, with the lowest concentrations recorded in the bays and the highest in the rivers. Fibers dominated over fragments in most environments (from 47% to 97%). The microplastic concentrations were related to the anthropogenic pressure on the environment, pointing out the necessity in a near future to identify the local sources of microplastics., (Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
38. Beta-Hemolytic Streptococcal Infective Endocarditis: Characteristics and Outcomes From a Large, Multinational Cohort.
- Author
-
Fernández Hidalgo N, Gharamti AA, Aznar ML, Almirante B, Yasmin M, Fortes CQ, Plesiat P, Doco-Lecompte T, Rizk H, Wray D, Lamas C, Durante-Mangoni E, Tattevin P, Snygg-Martin U, Hannan MM, Chu VH, and Kanafani ZA
- Abstract
Background: Beta-hemolytic streptococci (BHS) are an uncommon cause of infective endocarditis (IE). The aim of this study was to describe the clinical features and outcomes of patients with BHS IE in a large multinational cohort and compare them with patients with viridans streptococcal IE., Methods: The International Collaboration on Endocarditis Prospective Cohort Study (ICE-PCS) is a large multinational database that recruited patients with IE prospectively using a standardized data set. Sixty-four sites in 28 countries reported patients prospectively using a standard case report form developed by ICE collaborators., Results: Among 1336 definite cases of streptococcal IE, 823 were caused by VGS and 147 by BHS. Patients with BHS IE had a lower prevalence of native valve ( P < .005) and congenital heart disease predisposition ( P = .002), but higher prevalence of implantable cardiac device predisposition ( P < .005). Clinically, they were more likely to present acutely ( P < .005) and with fever ( P = .024). BHS IE was more likely to be complicated by stroke and other systemic emboli ( P < .005). The overall in-hospital mortality of BHS IE was significantly higher than that of VGS IE ( P = .001). In univariate analysis, variables associated with in-hospital mortality for BHS IE were age (odds ratio [OR], 1.044; P = .004), prosthetic valve IE (OR, 3.029; P = .022), congestive heart failure (OR, 2.513; P = .034), and stroke (OR, 3.198; P = .009)., Conclusions: BHS IE is characterized by an acute presentation and higher rate of stroke, systemic emboli, and in-hospital mortality than VGS IE. Implantable cardiac devices as a predisposing factor were more often found in BHS IE compared with VGS IE., (© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
- Published
- 2020
- Full Text
- View/download PDF
39. International Society of Cardiovascular Infectious Diseases Guidelines for the Diagnosis, Treatment and Prevention of Disseminated Mycobacterium chimaera Infection Following Cardiac Surgery with Cardiopulmonary Bypass.
- Author
-
Hasse B, Hannan MM, Keller PM, Maurer FP, Sommerstein R, Mertz D, Wagner D, Fernández-Hidalgo N, Nomura J, Manfrin V, Bettex D, Hernandez Conte A, Durante-Mangoni E, Tang TH, Stuart RL, Lundgren J, Gordon S, Jarashow MC, Schreiber PW, Niemann S, Kohl TA, Daley CL, Stewardson AJ, Whitener CJ, Perkins K, Plachouras D, Lamagni T, Chand M, Freiberger T, Zweifel S, Sander P, Schulthess B, Scriven JE, Sax H, van Ingen J, Mestres CA, Diekema D, Brown-Elliott BA, Wallace RJ Jr, Baddour LM, Miro JM, Hoen B, Athan E, Bayer A, Barsic B, Corey GR, Chu VH, Durack DT, Fortes CQ, Fowler V, Hoen B, Krachmer AW, Durante-Magnoni E, Miro JM, and Wilson WR
- Subjects
- Anti-Bacterial Agents therapeutic use, Cardiac Surgical Procedures adverse effects, Cardiac Surgical Procedures methods, Cardiology, Cardiopulmonary Bypass, Communicable Diseases, Equipment Contamination, Humans, Risk Factors, Societies, Medical, United Kingdom, Cross Infection diagnosis, Cross Infection drug therapy, Cross Infection microbiology, Cross Infection prevention & control, Mycobacterium isolation & purification, Mycobacterium Infections, Nontuberculous diagnosis, Mycobacterium Infections, Nontuberculous drug therapy, Mycobacterium Infections, Nontuberculous prevention & control
- Abstract
Mycobacterial infection-related morbidity and mortality in patients following cardiopulmonary bypass surgery is high and there is a growing need for a consensus-based expert opinion to provide international guidance for diagnosing, preventing and treating in these patients. In this document the International Society for Cardiovascular Infectious Diseases (ISCVID) covers aspects of prevention (field of hospital epidemiology), clinical management (infectious disease specialists, cardiac surgeons, ophthalmologists, others), laboratory diagnostics (microbiologists, molecular diagnostics), device management (perfusionists, cardiac surgeons) and public health aspects., (Copyright © 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
40. The association between vegetation size and surgical treatment on 6-month mortality in left-sided infective endocarditis.
- Author
-
Fosbøl EL, Park LP, Chu VH, Athan E, Delahaye F, Freiberger T, Lamas C, Miro JM, Strahilevitz J, Tribouilloy C, Durante-Mangoni E, Pericas JM, Fernández-Hidalgo N, Nacinovich F, Rizk H, Barsic B, Giannitsioti E, Hurley JP, Hannan MM, and Wang A
- Subjects
- Aged, Endocarditis, Bacterial mortality, Female, Humans, Male, Middle Aged, Prospective Studies, Survival Analysis, Time Factors, Endocarditis, Bacterial microbiology, Endocarditis, Bacterial surgery
- Abstract
Aims: In left-sided infective endocarditis (IE), a large vegetation >10 mm is associated with higher mortality, yet it is unknown whether surgery during the acute phase opposed to medical therapy is associated with improved survival. We assessed the association between surgery and 6-month mortality as related to vegetation size., Methods and Results: Patients with definite, left-sided IE (2008-2012) from The International Collaboration on Endocarditis prospective, multinational registry were included. We compared clinical characteristics and 6-month mortality (by Cox regression with inverse propensity of treatment weighting) between patients with vegetation size ≤10 mm vs. >10 mm in maximum length by surgical treatment strategy. A total of 1006 patients with left sided IE were included; 422 with a vegetation size ≤10 mm (median age 66.0 years, 33% women) and 584 (median age 58.4 years, 34% women) patients with a large vegetation >10 mm. Operative risk by STS-IE score was similar between groups. Embolic events occurred in 28.4% vs. 44.3% (P < 0.001), respectively. Patients with a vegetation >10 mm was associated with higher 6-month mortality (25.1% vs. 19.4% for small vegetation, P = 0.035). However, after propensity adjustment, the association with higher mortality persisted only in patients with a large vegetation >10 mm vs. ≤10 mm: hazard ratio (HR) 1.55 (1.27-1.90); but only in patients with large vegetation managed medically [HR 1.86 (1.48-2.34)] rather than surgically [HR 1.01 (0.69-1.49)]., Conclusion: Left-sided IE with vegetation size >10 mm was associated with an increased mortality at 6 months in this observational study but was dependent on treatment strategy. For patients with large vegetation undergoing surgical treatment, survival was similar to patients with smaller vegetation size., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
41. Corrigendum to "association between the timing of surgery for complicated, left-sided infective endocarditis and survival", American HeartJournal 2019, volume 210, April 2019, pages 108-116.
- Author
-
Wang A, Chu VH, Athan E, Delahaye F, Freiberger T, Lamas C, Miro JM, Strahilevitz J, Tribouilloy C, Durante-Mangoni E, Pericas JM, Fernández-Hidalgo N, Nacinovich F, Barsic B, Giannitsioti E, Hurley JP, Hannan MM, and Park LP
- Published
- 2019
- Full Text
- View/download PDF
42. Preparation, Characterization and Photocatalytic Activity of La-Doped Zinc Oxide Nanoparticles.
- Author
-
Nguyen LTT, Nguyen LTH, Duong ATT, Nguyen BD, Quang Hai N, Chu VH, Nguyen TD, and Bach LG
- Abstract
Lanthanum (La)-doped zinc oxide nanoparticles were synthesized with different La concentrations by employing a gel combustion method using poly(vinyl alcohol) (PVA). The as-synthesized photocatalysts were characterized using various techniques, including X-ray diffraction (XRD), transmission electron microscopy (TEM), energy dispersive X-ray analysis (EDX), photoluminescence (PL) spectroscopy, and UV-visible absorption spectroscopy. The average size of ZnO nanoparticles decreased from 34.3 to 10.3 nm with increasing concentrations of La, and the band gap, as evaluated by linear fitting, decreased from 3.10 to 2.78 eV. Additionally, it was found that the photocatalytic activity of doped samples, as investigated by using methyl orange dye under visible lights, improved in response to the increase in La concentration. The decomposition of methyl orange reached 85.86% after 150 min in visible light using La0.1Zn0.9O as the photocatalyst.
- Published
- 2019
- Full Text
- View/download PDF
43. Epidemiology of infection in mechanical circulatory support: A global analysis from the ISHLT Mechanically Assisted Circulatory Support Registry.
- Author
-
Hannan MM, Xie R, Cowger J, Schueler S, de By T, Dipchand AI, Chu VH, Cantor RS, Koval CE, Krabatsch T, Hayward CS, Nakatani T, and Kirklin JK
- Subjects
- Adult, Aged, Female, Heart-Lung Transplantation, Humans, International Cooperation, Male, Middle Aged, Societies, Medical, Young Adult, Heart Failure surgery, Heart-Assist Devices adverse effects, Prosthesis-Related Infections epidemiology, Prosthesis-Related Infections etiology, Registries
- Abstract
Background: Despite advances in device technology and treatment strategies, infection remains a major cause of adverse events (AEs) in mechanical circulatory support (MCS) patients. To characterize the epidemiology of MCS infection, we examined the type, location, and timing of infection in the International Society for Heart and Lung Transplantation Registry (ISHLT) for Mechanically Assisted Circulatory Support (IMACS) over 3 years, 2013 to 2015., Methods: Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) definitions were used to categorize AE infections occurring in MCS patients within IMACS. The IMACS infection variables were mapped to ISHLT definitions for infection where feasible. Three categories of MCS infection were defined as ventricular assist device (VAD) specific, VAD related, and non-VAD., Results: There were 10,171 patients enrolled from January 2013 through December 2015. Infection was the most common AE, with 3,788 patients (37%) experiencing ≥ 1 infection, and 6,758 AE infections reported overall. Non-VAD infection was the largest category, 4,501: 34.0% pneumonias, 30.6% non-VAD-related bloodstream infections (BSIs), 24.15% urinary tract infections (UTIs), and 10.2% gastrointestinal infections. VAD-specific infection was the second largest category, 1,756: 82.9% driveline, 12.8% pocket, and 4.3% pump/or cannula infections. VAD-related infection was the smallest category, 501: 47.5% BSIs, 47.5% mediastinitis, and 5.0% mediastinitis/pocket infections. All 3 categories were more frequently reported ≤ 3 months after implant., Conclusions: Non-VAD infection, including pneumonia, BSI, UTI, and gastrointestinal infection, was the leading category of infection in MCS patients and the most frequently reported ≤ 3 months after implant. These results provide evidence to support resourcing and strengthening infection prevention strategy early after implantation in MCS., (Copyright © 2019 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
44. Association between the timing of surgery for complicated, left-sided infective endocarditis and survival.
- Author
-
Wang A, Chu VH, Athan E, Delahaye F, Freiberger T, Lamas C, Miro JM, Strahilevitz J, Tribouilloy C, Durante-Mangoni E, Pericas JM, Fernández-Hidalgo N, Nacinovich F, Barsic B, Giannitsioti E, Hurley JP, Hannan MM, and Park LP
- Subjects
- Abscess mortality, Acute Disease, Adult, Aged, Endocarditis, Bacterial pathology, Female, Heart Failure epidemiology, Heart Failure etiology, Hospitalization, Humans, Male, Middle Aged, Patient Transfer statistics & numerical data, Propensity Score, Proportional Hazards Models, Prospective Studies, Risk Factors, Staphylococcal Infections mortality, Staphylococcus aureus, Surgical Procedures, Operative, Endocarditis, Bacterial mortality, Endocarditis, Bacterial surgery, Time-to-Treatment
- Abstract
Background: In patients with active infective endocarditis (IE), the relationship between timing of surgery and survival is uncertain. The objective was to evaluate clinical characteristics associated with timing of surgery and the association between surgical timing and 6-month survival in complicated, left-sided IE., Methods: In a prospective, multicenter, observational registry (The International Collaboration on Endocarditis-PLUS, registry from 2008 to 2012), clinical factors associated with timing of surgery during the index hospitalization were determined among 485 adult patients with definite, complicated, left-sided IE who underwent cardiac surgery during their index hospitalization. The relationship between early surgical intervention (<7 days from admission to surgery center) and outcome after surgery was analyzed. The primary end point of the study was 6-month survival., Results: The median time to surgery from admission to surgical center was 7 (interquartile range 2-15) days. Patients who underwent earlier surgery were more likely transferred to the surgical center (74.2% vs 46.4%, P < .001) and had a lower percentage of preexisting heart failure (before IE diagnosis) (6.0% vs 17.3%, P < .001) but higher rate of acute heart failure (53.2% vs 38.4%, P = .001). Variables independently associated with surgery <7 days from admission were patient transfer, acute heart failure, and nonelective surgical status (C-index = 0.84), but predicted operative risk was not. Cox proportional hazards modeling with inverse probability of treatment weighting found that earlier surgery was associated with a trend toward higher 6-month mortality compared with later surgery (hazard ratio = 1.68, 95% CI 0.97-2.96; P = .065), particularly surgery within 2 days of admission or transfer. Mortality was significantly associated with operative risk and complicated IE, including Staphylococcus aureus infection and presence of abscess., Conclusions: Earlier surgery in IE is strongly associated with acute heart failure and surgical urgency. After adjustment for operative risk and IE complications, earlier surgery <7 days from admission was associated with a trend toward higher 6-month overall mortality compared with surgery later in the index hospitalization., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
45. Reply: Intravenous Drug Use-Associated Endocarditis Complicating Research of Antibiotic Prophylaxis and Guideline Recommendations.
- Author
-
Thornhill MH, Dayer MJ, Chu VH, O'Gara PT, and Baddour LM
- Subjects
- American Heart Association, Humans, Incidence, Antibiotic Prophylaxis, Endocarditis
- Published
- 2019
- Full Text
- View/download PDF
46. Trends in Drug Use-Associated Infective Endocarditis and Heart Valve Surgery, 2007 to 2017: A Study of Statewide Discharge Data.
- Author
-
Schranz AJ, Fleischauer A, Chu VH, Wu LT, and Rosen DL
- Subjects
- Adult, Aged, Female, Heart Valve Diseases complications, Heart Valve Diseases surgery, Heart Valve Prosthesis Implantation economics, Hospital Charges, Hospitalization economics, Humans, Length of Stay, Male, Middle Aged, North Carolina epidemiology, Retrospective Studies, Risk Factors, Endocarditis complications, Endocarditis surgery, Heart Valve Prosthesis Implantation statistics & numerical data, Heart Valves surgery, Hospitalization statistics & numerical data, Substance-Related Disorders complications
- Abstract
Background: Drug use-associated infective endocarditis (DUA-IE) is increasing as a result of the opioid epidemic. Infective endocarditis may require valve surgery, but surgical treatment of DUA-IE has invoked controversy, and the extent of its use is unknown., Objective: To examine hospitalization trends for DUA-IE, the proportion of hospitalizations with surgery, patient characteristics, length of stay, and charges., Design: 10-year analysis of a statewide hospital discharge database., Setting: North Carolina hospitals, 2007 to 2017., Patients: All patients aged 18 years or older hospitalized for IE., Measurements: Annual trends in all IE admissions and in IE hospitalizations with valve surgery, stratified by patients' drug use status. Characteristics of DUA-IE surgical hospitalizations, including patient demographic characteristics, length of stay, disposition, and charges., Results: Of 22 825 IE hospitalizations, 2602 (11%) were for DUA-IE. Valve surgery was performed in 1655 IE hospitalizations (7%), including 285 (17%) for DUA-IE. Annual DUA-IE hospitalizations increased from 0.92 to 10.95 and DUA-IE hospitalizations with surgery from 0.10 to 1.38 per 100 000 persons. In the final year, 42% of IE valve surgeries were performed in patients with DUA-IE. Compared with other surgical patients with IE, those with DUA-IE were younger (median age, 33 vs. 56 years), were more commonly female (47% vs. 33%) and white (89% vs. 63%), and were primarily insured by Medicaid (38%) or uninsured (35%). Hospital stays for DUA-IE were longer (median, 27 vs. 17 days), with higher median charges ($250 994 vs. $198 764). Charges for 282 DUA-IE hospitalizations exceeded $78 million., Limitation: Reliance on administrative data and billing codes., Conclusion: DUA-IE hospitalizations and valve surgeries increased more than 12-fold, and nearly half of all IE valve surgeries were performed in patients with DUA-IE. The swell of patients with DUA-IE is reshaping the scope, type, and financing of health care resources needed to effectively treat IE., Primary Funding Source: National Institutes of Health.
- Published
- 2019
- Full Text
- View/download PDF
47. Cardiovascular Implantable Electronic Device Infections.
- Author
-
Arnold CJ and Chu VH
- Subjects
- Humans, Risk Factors, Heart Diseases etiology, Prostheses and Implants adverse effects, Prosthesis-Related Infections etiology
- Abstract
Infections associated with cardiac implantable electronic devices are increasing and are associated with significant morbidity and mortality. This article reviews the epidemiology, microbiology, and risk factors for acquisition of these infections. The complex diagnostic and management strategies associated with these serious infections are reviewed with an emphasis on recent updates and advances, as well as existing controversies. Additionally, the latest in preventative strategies are reviewed., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
48. Device-Associated Infections.
- Author
-
Chu VH
- Subjects
- Animals, Humans, Equipment and Supplies adverse effects, Infections etiology
- Published
- 2018
- Full Text
- View/download PDF
49. Injection Drug Use-Associated Infective Endocarditis-Reply.
- Author
-
Wang A, Gaca JG, and Chu VH
- Subjects
- Humans, Injections, Endocarditis, Endocarditis, Bacterial
- Published
- 2018
- Full Text
- View/download PDF
50. Antibiotic Prophylaxis and Incidence of Endocarditis Before and After the 2007 AHA Recommendations.
- Author
-
Thornhill MH, Gibson TB, Cutler E, Dayer MJ, Chu VH, Lockhart PB, O'Gara PT, and Baddour LM
- Subjects
- Adolescent, Adult, Aged, Antibiotic Prophylaxis trends, Databases, Factual standards, Databases, Factual trends, Endocarditis, Bacterial diagnosis, Female, Health Insurance Portability and Accountability Act trends, Humans, Incidence, Male, Middle Aged, United States epidemiology, Young Adult, American Heart Association, Antibiotic Prophylaxis standards, Endocarditis, Bacterial epidemiology, Endocarditis, Bacterial prevention & control, Health Insurance Portability and Accountability Act standards, Practice Guidelines as Topic standards
- Abstract
Background: The American Heart Association updated its recommendations for antibiotic prophylaxis (AP) to prevent infective endocarditis (IE) in 2007, advising that AP cease for those at moderate risk of IE, but continue for those at high risk., Objectives: The authors sought to quantify any change in AP prescribing and IE incidence., Methods: High-risk, moderate-risk, and unknown/low-risk individuals with linked prescription and Medicare or commercial health care data were identified in the Truven Health MarketScan databases from May 2003 through August 2015 (198,522,665 enrollee-years of data). AP prescribing and IE incidence were evaluated by Poisson model analysis., Results: By August 2015, the 2007 recommendation change was associated with a significant 64% (95% confidence interval [CI]: 59% to 68%) estimated fall in AP prescribing for moderate-risk individuals and a 20% (95% CI: 4% to 32%) estimated fall for those at high risk. Over the same period, there was a barely significant 75% (95% CI: 3% to 200%) estimated increase in IE incidence among moderate-risk individuals and a significant 177% estimated increase (95% CI: 66% to 361%) among those at high risk. In unknown/low-risk individuals, there was a significant 52% (95% CI: 46% to 58%) estimated fall in AP prescribing, but no significant increase in IE incidence., Conclusions: AP prescribing fell among all IE risk groups, particularly those at moderate risk. Concurrently, there was a significant increase in IE incidence among high-risk individuals, a borderline significant increase in moderate-risk individuals, and no change for those at low/unknown risk. Although these data do not establish a cause-effect relationship between AP reduction and IE increase, the fall in AP prescribing in those at high risk is of concern and, coupled with the borderline increase in IE incidence among those at moderate risk, warrants further investigation., (Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.